



28th CINP WORLD CONGRESS OF NEUROPSYCHOPHARMACOLOGY

CINP – The International College of Neuropsychopharmacology

3–7 June 2012

Stockholm

Sweden



www.cinp2012.com

www.cinp.org

- Final Announcement
- Call for Posters

CINP and Congress President

Prof. Hans-Jürgen Möller, Germany

Host Organisation – CINP

Central Office

Glenfinnan Suite, Braeview House

9/11 Braeview Place, East Kilbride

Glasgow G74 3XH, Scotland, UK

Phone: +44 (0) – 1355 244 930

Fax: +44 (0) – 1355 249 959

Email: cinp@northernnetworking.co.uk

www.cinp.org

Congress Office

CPO HANSER®
SERVICE

Hamburg Office

Hanser & Co GmbH

Zum Ehrenhain 34

22885 Barsbüttel

Germany

Phone: +49 – 40 – 670 88 20

Fax: +49 – 40 – 670 32 83

Email: cinp2012@cpo-hanser.de

Congress Venue

Stockholmsmässan

Mässvägen 1 Älvsjö

Stockholmsmässan AB

125 80 Stockholm

Sweden

Stockholm – The City of Noble Prize Winners



Photographs © Stockholm Visitors Board

Table of Contents

	page
Welcome Address	4
Brief Description of CINP/Committees and Organisers	5
Preliminary Programme Schedule/Overview	7
Scientific Session Information	8
Preliminary Scientific Programme	9
Call for Poster Abstracts	20
Brief Biography of Plenary Speakers	22
CINP Awards	27
Congress Registration	28
General Information	30
Hotel Accomodation	32
City of Stockholm	33
Supporting Programme	34
Application Forms for CINP Awards	37
Registration Form	41

Dates to remember

- 05 January 2012 → Deadline for CINP Awards
- 31 January 2012 → First deadline for early registration fee
- 31 January 2012 → Deadline for poster abstract submission
- 31 January 2012 → Deadline for receiving speaker abstracts for accepted symposia
- 02 May 2012 → Second deadline for early registration fee
- 03 June 2012 → Opening Ceremony of CINP 2012

Welcome Address by the CINP President and the Chair of the Local Organising Committee



Hans-Jürgen
Möller

Dear Colleague

The International College of Neuropsychopharmacology (CINP) invites you to attend our 28th Biennial World Congress hosted in one of the most beautiful capital cities in Europe, Stockholm, Sweden.

We are very pleased to report that yet again we have received a large number of applications for symposia for the 28th CINP World Congress of Neuropsychopharmacology. The International Scientific Programme Committee, at a meeting in March 2011, spent two days deliberating over the many excellent suggestions and finally managed to select 38 in total. These symposia are listed from page 9 of this brochure. In addition to the regular symposia we are now developing the Educational Track for the meeting, details of which will be regularly updated on our website.

Our seven Plenary speakers in 2012 are truly world class scientists. We are delighted that they have all agreed to participate in the meeting giving you, the delegate, an opportunity to hear first hand from these eminent speakers in their field. Full details of all our Plenary speakers can be found on pages 22 to 26.



Torgny H. Svensson

You, as a delegate, can also contribute to the science. We would like to encourage you to consider submitting a poster for the 28th CINP World Congress and instructions on how to do this are contained on page 20. It is very important to the scientific field to see and hear the latest developments that are up and coming and a poster is the ideal forum to present this science. We would also like to encourage our younger colleagues to consider submitting a poster which will give you access to show your work to all the delegates attending our World Congress.

CINP is a world organisation devoted to the education and development of our science. By contributing or attending this Congress in Stockholm you will have the opportunity to participate in one of the top global scientific meetings. We are particularly fortunate to be able to enjoy our five days of science set in the beautiful city of Stockholm.

For those who have not had the opportunity to sample the Swedish way of life this is a must. Stockholm, the capital city of Sweden, is built on 14 islands connected by 57 bridges. Rich in cultural life and with a 750 year history this congress will offer you the opportunity to enjoy stimulating days of science and cultural evenings. This is therefore a compelling and fascinating reason to attend our congress as there are very few congresses which can boast taking place in a location steeped in history and culture. We are delighted to be able to bring this meeting to the purpose built congress centre in Stockholm, which is located close to the city centre and is accessible by high speed transport links. Stockholm itself offers a wide range of all types of accommodation and many lively and international restaurants.

We look forward to welcoming you in Stockholm in 2012.

A handwritten signature in black ink, appearing to read 'H. Möller', written in a cursive style.

Prof. Hans-Jürgen Möller
CINP President

A handwritten signature in black ink, appearing to read 'Torgny H. Svensson', written in a cursive style.

Prof. Torgny H. Svensson
Chairman of the Local Organising
Committee

Brief Description of CINP/Committees and Organisers

The International College of Neuropsychopharmacology (CINP) is a truly worldwide organisation established over 50 years ago with its registered office in Zurich, Switzerland. Membership is on an individual basis and we offer members the opportunity to become part of this knowledgeable group of scientists who work at the international level.

Holding regular meetings in the form of Thematic Meetings, Regional Meetings, Training Programmes and the Biennial World Congress, CINP reaches interested researchers all over the world. CINP is dedicated to promoting research and education on a worldwide basis.

The Executive Committee and Councillors of CINP are nominated by the membership and serve as officers of the College for a minimum of four years. These individuals cover a wide range of disciplines within the field from psy-

chiatrists, psychopharmacologists, basic and clinical researchers and clinical psychologists. CINP relies on its many subcommittees who undertake a variety of activities for the College.

Membership of the College is available to any individual to apply for. Membership applications are reviewed by a dedicated committee on a regular basis.

The International Journal of Neuropsychopharmacology (IJNP) with a steadily increasing impact factor, has become a sought after publication. Articles are received and reviewed independently and are published after a rigorous review process.

For more information about the College please go to our interactive web site at www.cinp.org

CINP Executive Committee 2010 – 2012

President

Hans-Jürgen Möller, Germany

Past President

Robert H. Belmaker, Israel

Vice Presidents

Jeffrey Lieberman, USA

Alexandra Sulcova, Czech Republic

President Elect

Anthony Phillips, Canada

Secretary

Shitij Kapur, United Kingdom

Treasurer

Brian Dean, Australia

Councillors

Alan Frazer, USA

Nancy Y. Ip, Hong Kong

Klaus Peter Lesch, Germany

Jun Soo Kwon, Korea

Philip Mitchell, Australia

Dan Rujescu, Germany

Barbara Sahakian, United Kingdom

Toshikazu Saito, Japan

Gregers Wegener, Denmark

Moussa Youdim, Israel

Alan Young, Canada

Local Organising Committee

Chairman

Torgny H. Svensson, Sweden

Co-Chairman

Lars Farde, Sweden

Ole Andreassen, Norway

Simon Cervenka, Sweden

Elias Eriksson, Sweden

Aleksander Mathé, Sweden

Gregers Wegener, Denmark

International Scientific Programme Committee

Chairman

Anthony Phillips, Canada

Co-Chair

Pierre Blier, Canada

Robert H. Belmaker, Israel

Simon Cervenka, Sweden

Brian Dean, Australia

Lars Farde, Sweden

Alan Frazer, USA

Anthony Grace, USA

Jarmo Hietala, Finland

Nancy Y. Ip, Hong Kong

Shitij Kapur, United Kingdom

Maria Karayiorgou, USA

Siegfried Kasper, Austria

Min-Soo Lee, Korea

Jeffrey Lieberman, USA

Hans-Jürgen Möller, Germany

Dan Rujescu, Germany

Barbara Sahakian, United Kingdom

Alexandra Sulcova, Czech Republic

Torgny H. Svensson, Sweden

Shigeto Yamawaki, Japan

International Advisory Board

Huda Akil, USA

A. Carlo Altamura, Italy

Garcia Julio Bobes, Spain

Helena Calil, Brazil

J. F. William Deakin, United Kingdom

Wolfgang Fleischhacker, Austria

Sophia Frangou, United Kingdom

Enrique Galli, Peru

Daniela Jezova, Slovak Republic

Jun Soo Kwon, Korea

Brian Leonard, Ireland

Klaus-Peter Lesch, Germany

Herbert Meltzer, USA

Julien Mendlewicz, Belgium

Philip Mitchell, Australia

E. Mohandas, India

Jean-Pierre Olie, France

Eugene S. Paykel, United Kingdom

Giorgio Racagni, Italy

Janusz Rybakowski, Poland

Toshikazu Saito, Japan

Elizabeth Scarr, Australia

Vidita A. Vaidya, India

Gregers Wegener, Denmark

Moussa Youdim, Israel

Alan Young, Canada

Ambassadors Programme

CINP has created an Ambassadors Programme to help make the 28th CINP World Congress in Stockholm an extraordinary and unforgettable event. Prominent representatives from all aspects of our field of science and from countries all over the world are currently active in this programme.

Ambassadors

Carlo Altamura, Italy
 Ajit Avasthi, India
 Charles Baddoura, Lebanon
 Thomas A. Ban, Canada
 David Baron, USA
 Michael Berk, Australia
 Istvan Bitter, Hungary
 Blier Pierre, USA
 Julio Bobes Garcia, Spain
 Graham Burrows, Australia
 Brian Dean, Australia
 David Dunner, USA
 Mahmoud M. Elhabiby, Egypt
 Wolfgang Fleischhacker, Austria
 Kostas N Fountoulakis, Greece
 Alan Frazer, USA
 Silvana Galderisi, Italy
 Enrique Galli, Peru
 Péter Gaszner, Hungary
 Ira D. Glick, USA
 Bai Han, R. China
 Catherine Harmer, United Kingdom
 Gerhard Heinze, Mexico
 Cyril Höschl, Czech-Republic
 Daniela Jezova, Slovak Republic
 Gordon Johnson, Australia
 Siegfried Kasper, Austria
 Sidney H. Kennedy, Canada
 Sung Kil Min, Korea
 Valery Krasnov, Russia
 Hong Shick Lee, Korea
 Brian Leonard, Ireland
 Jeffrey Lieberman, USA
 Juan J. López-Ibor, Italy
 Bruno Millet, France
 Anu Kant Mital, India
 Philip Mitchell, Australia
 Sergey Mosolov, Russia
 Ahmed Okasha, Egypt
 Jorge Ospina-Duque, Colombia
 Christos Pantelis, Australia
 Eugene S. Paykel, United Kingdom
 Giorgio Racagni, Italy
 Andreas Reif, Germany

Maria Rettenbacher, Austria
 Dan Rujescu, Germany
 Janusz Rybakowski, Poland
 Toshikazu Saito, Japan
 S. Charles Schulz, USA
 Isaac Schweitzer, Australia
 Edith Mirta Serfaty, Argentina
 Alessandro Serretti, Italy
 Constantin R. Soldatos, Greece
 Manit Srisurapanont, Thailand
 Daniela Stein, South Africa
 Alexandra Sulcova, Czech Republic
 Carol Tamminga, USA
 Rajiv Tandon, USA
 Andi J. Tanras, Indonesia
 Florence Thibaut, France
 Si Tianmei, China
 Livia Vavrusova, Slovak Republic
 Jaime Vengoechea, Colombia
 Eduard Vieta, Spain
 Mohandas Warriar, India
 Noppamars Wongwitdecha, Thailand
 Shigeto Yamawaki, Japan
 Yukio Yoneda, Japan
 Jin-Sang Yoon, Korea
 Allan Young, Canada
 Kunio Yui, Japan

Ambassadors as of August 2011

Scandinavian Advisory Board for the LOC

Anna Åberg-Wistedt, Sweden
 Jørgen G. Bramness, Norway
 Jensen Anders Fink, Denmark
 Kjell Fuxe, Sweden
 Tove Gunnarsson, Sweden
 Jarmo Hietala, Finland
 Thomas Hökfelt, Sweden
 Jari Tiihonen, Finland
 Anders Tingström, Denmark
 Poul Videbech, Denmark
 Gregers Wegener, Denmark

Preliminary Programme Schedule/Overview

Time \ Date	3 June 2012	4 June 2012	5 June 2012	6 June 2012	7 June 2012
07.45 – 08.45		Morning Industry Satellite Symposia 60 mins			
09.00 – 09.45		Plenary Lecture 45 mins			09.00 – 11.00 Symposia 120 mins
09.45 – 10.00		Coffee break			
10.00 – 12.00		Symposia 120 mins Educational Workshops 120 mins Pro/Con Debates 60 mins			11.00 – 11.15 Coffee break
					11.15 – 12.00 Plenary Lecture 45 mins
12.00 – 14.00		12.15 – 13.45 h Industry satellite symposia 90 mins 12.00 – 14.00 h Lunch break			Closing
14.00 – 14.45		Plenary Lecture 45 mins			
14.45 – 15.00		Coffee break			
15.00 – 17.00		Symposia 120 mins Educational Workshops 120 mins Pro/Con Debates 60 mins			
17.15 – 18.45		Industry satellite symposia 90 mins Poster tours			
18.45 – 21.30	Opening & Welcome 18.00 – 21.30				

Scientific Session Information

Plenary Lectures

Plenary lecturers present 45 minute talks at the beginning of each morning and afternoon session Monday to Wednesday. A plenary lecture will close the Congress on Thursday. These speakers are chosen in recognition of their exceptional achievements in basic or clinical research and the talks will include material of interest to both basic science and clinical audiences.

Symposia

Symposia of two-hour duration cover latest advances in basic and clinical neuropsychopharmacology, biological psychiatry, drug development, public policy issues relevant to the field, mental health, mental illness and treatment outcome.

Pro and Con Debates

During the daily 60-minute debates current controversial issues will be introduced and discussed. One moderator and two discussants (pro and con) will raise interactive and lively debates.

Educational Workshops

Educational Workshops are sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides substantial audience participation and should be highly interactive.

Poster Sessions

These sessions offer an effective forum for the exchange of information and a means to communicate ideas, research, and programmes. Poster authors will present and discuss their results in these highly interactive sessions in various fields.

Satellite Symposia

Satellite symposia will be organised and presented by pharmaceutical companies in consultation with the International Scientific Programme Committee. Breakfast, lunch and evening symposia are scheduled for 60 and 90 minutes.



Photographs © Stockholm Visitors Board

Preliminary Scientific Programme

Monday, 4 June 2012

09.00 – 09.45

PL-01 ► Plenary Lecture

Topic: Schizophrenia

Schizophrenia: Course, causes and developments in drug treatmentSpeaker: *Hans Jürgen Möller, Germany*

10.00 – 12.00

S-01 ► Symposium

Topic: Antipsychotics

Track: Translational

Dopamine receptors, noradrenergic mechanisms and D2 containing heteromers as targets for antipsychotic drugsChair: *Kjell Fuxe, Sweden***Antipsychotics – are we targeting the right system but the wrong end**Shitij Kapur, *United Kingdom***Combined utility of antipsychotic and antidepressant drugs: Scientific rationales**Torgny Svensson, *Sweden***Putative D2 receptor containing heteromers in the ventral striatum and their relevance for treatment of schizophrenia**Kjell Fuxe, *Sweden***The DA receptor-transporter complexes and increased D2 receptor dimerization: Relevance for schizophrenia**Fang Liu, *Canada*

10.00 – 12.00

S-02 ► Symposium

Topic: Depression

Track: Clinical

Management of treatment-resistant major depressionChair: *George I Papakostas, USA***Pharmacotherapeutic strategies for adults with major depressive disorder**George I Papakostas, *USA***Pharmacotherapeutic strategies for adults with bipolar depression**Michael Bauer, *Germany***Somatic therapies – Brain stimulation methods**Mark S George, *USA*Speaker: *Jan K Buitelaar, Netherlands*

10.00 – 12.00

S-03 ► Symposium

Topic: Addictive Disorders

Track: Basic

Cocaine-induced changes in glutamate neuroplasticity in developing and mature neuronal circuitsChair: *Fabio Fumagalli, Italy***Cocaine-induced changes in glutamate neuroplasticity in developing and mature mesolimbic circuits**Camilla Bellone, *Switzerland***Cocaine experience modulates synaptic transmission in the habenula complex**Manuel Mamei, *France***Neuroplastic changes following repeated exposure to cocaine during adolescence: Focus on the glutamatergic system**Fabio Fumagalli, *Italy***Cortico-striatal glutamate dysregulation in an animal model of cocaine addiction and relapse**Ronald See, *Italy*

10.00 – 12.00

S-04 ► Symposium

Topic: Pharmacogenetics/Pharmacokinetics

Track: Translational

Insights for personalized medicine in psychiatryChair: *Claes Wahlestedt, USA***Complex regulation of gene expression in brain**Claes Wahlestedt, *USA***Gene x environment interactions in the prediction of response to antidepressant treatment**Elisabeth Binder, *Germany***Personalized medicine and the management of TRD**Charles Nemeroff, *USA***Pharmacogenetics of alcohol reward and therapeutic response to naltrexone**Markus Heilig, *Sweden*

Preliminary Scientific Programme

Monday, 4 June 2012

10.00 – 12.00

S-05 ► Symposium

Topic: Post Traumatic Stress Disorder
Track: Clinical

Mechanism of PTSD: From genes and epigenetics to neurocircuits and endophenotype

Chair: *Shigeru Morinobu, Japan*

Searching for epigenetic biomarkers in PTSD

Shigeru Morinobu, Japan

Genetic approaches to understanding posttraumatic stress disorder

Kerry Ressler, USA

Stress, emotion and cognition: Lessons from studying PTSD neurocircuitry

Israel Liberzon, USA

Intrinsic network abnormalities in post-traumatic stress disorder

Ruth Lanius, Canada

10.00 – 12.00

W-01 ► Workshop

Track: Educational

Generalised anxiety disorder: Update on pharmacological treatment

10.00 – 11.00

D-01 ► Pro and Con Debate

Topic: Genetics

Track: Educational

Do genetics provide new drugable targets?

11.00 – 12.00

D-02 ► Pro and Con Debate

Track: Educational

Is beta amyloid a target for successful treatment of Alzheimer's disease?

14.00 – 14.45

PL-02 ► Plenary Lecture

Topic: Addictive Disorders

Addiction: From molecules to neuronal circuits

Speaker: *Nora Volkow, USA*

15.00 – 17.00

S-06 ► Symposium

Topic: Antidepressants
Track: Basic

The glutamate synapse and its regulation: An opportunity for novel pharmacologic approaches in mood/anxiety disorders

Chair: *Maurizio Popoli, Italy*

Targeting glutamate clearance in the development of treatments anxiety and depression: Focus on EAATS

Gerard Sanacora, USA

Modulating the NMDA receptor complex in developing therapeutics for bipolar disorder and major depressive disorder

Carlos Zarate, USA

Targeting glutamate release as a testing ground for compounds with antidepressant/anxiolytic action

Maurizio Popoli, Italy

Metabotropic glutamate receptors as therapeutic targets for anxiety and depression: Focus on mGluR7

John Cryan, Ireland

15.00 – 17.00

S-07 ► Symposium

Topic: Suicide

Track: Clinical

Suicide: Pathophysiology, psychopharmacology and biomarkers

Chair: *William Bunney, USA*

Suicide: Social, psychological, biological and genetic risk factors

William Bunney, USA

The role of the CRHR1 gene in treatment of males with suicidal depression

Danuta Wasserman, Sweden

The pharmacogenetics of SSRI medication in children and adolescents

Alan Apter, USA

Noradrenergic and serotonergic pathways and the stress-diathesis model of suicidal behaviour

John Mann, USA

Preliminary Scientific Programme

Monday, 4 June 2012

15.00 – 17.00

S-08 ► Symposium

Topic: Obsessive-Compulsive Disorders
Track: Translational

The neurobiology of compulsivity and OCD: From basic science to clinical practice

Chair: *Anthony Grace, USA*

Symptomatology and pharmacotherapy of obsessive-compulsive disorder

Daniel Stein, South Africa

Unraveling neural mechanisms of compulsivity using the signal attenuation rat model

Daphna Joel, Israel

The translational neuroscience of OCD

Trevor Robbins, United Kingdom

Deep brain stimulation of the ventral striatum modulates mPFC/OFC coherence: A model for OCD pathophysiology

Anthony Grace, USA

15.00 – 17.00

S-09 ► Symposium

Topic: Depression
Track: Translational

Neuropeptides and mental diseases

Chair: *Tomas Hökfelt, Sweden*

Role of orexin/hypocretin in panic and other stress disorders

Ananthan Shekhar, USA

CRH1 Receptor antagonists – Back on the map

Florian Holsboer, Germany

Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia

Jonathan Sebat, USA

Galanin and galanin receptors in depression – focus on human brain

Tomas Hökfelt, Sweden

15.00 – 17.00

S-10 ► Symposium

Topic: Panic Disorders
Track: Translational

Putative abnormalities in Orexin and GABA metabolism in panic disorder

Chair: *Andrew Goddard, USA*

Orexin and psychiatric symptoms in suicide attempters

Lena Brundin, Sweden

GABA imaging findings in panic disorder measured by ¹H MRS

Ulrike Dydak, USA

Resting-state functional connectivity in panic disorder

Yong-Wook Shin, Republic of Korea

Clinical studies of Orexin and GABA function in panic and related disorders

Andrew Goddard, USA

15.00 – 17.00

W-02 ► Workshop

Topic: Addictive Disorders
Track: Educational

Update on drug treatment of alcohol abuse disorders

Preliminary Scientific Programme

 Tuesday, 5 June 2012

 09.00 – 09.45

PL-03 ▶ Plenary Lecture

Topic: Depression

Depressing tales of adult neurogenesis: A hard look at the evidenceSpeaker: *Pasko Rakic, USA*

 10.00 – 12.00

S-11 ▶ Symposium

Topic: Psychoneuroimmunology

Track: Clinical

Mental health and the immune systemChair: *Brian Leonard, Ireland***Antidepressants as anti-inflammatory agents in the treatment of depression: Fact or fiction?***Brian Leonard, Ireland***The Role of tryptophan catabolites in the pathogenesis of depression: Lessons from interferon-alpha***Charles Raison, USA***The immune system and the kynurenine pathway in schizophrenia: Pathophysiological and therapeutic aspects***Markus Schwarz, Germany***Oxidative and immune biomarkers as targets for the development of novel therapies***Michael Berk, Australia*

 10.00 – 12.00

S-12 ▶ Symposium

Topic: Schizophrenia

Track: Translational

Oxidative stress, and the development of mental disordersChair: *Patricio O'Donnell, USA***Mood disorders and mitochondrial dysfunction***Trevor Young, Canada***Long term consequences of brain oxidative-stress during early postnatal life***Margarita Behrens, USA***Oxidative stress in prefrontal cortical parvalbumin interneurons in the neonatal ventral hippocampal lesion model of schizophrenia***Patricio O'Donnell, USA***Redox dysregulation, inhibitory-excitatory imbalance and myelination impairment in schizophrenia***Kim Do, Switzerland*

 10.00 – 12.00

S-13 ▶ Symposium

Topic: Post Traumatic Stress

Track: Translational

Molecular mechanisms and prophylaxis in PTSD, contributions from prospective and longitudinal studiesChair: *Eric Vermetten, The Netherlands***Biological correlates of PTSD: From endocrinology to molecular biology***Rachel Yehuda, USA***True prospective studies in military cohorts; central and peripheral regulation of combat stress***Eric Vermetten, Netherlands***Hydrocortisone in the golden hours and PTSD trajectory – Clinical and animal studies***Joseph Zohar, Israel***Title to be announced**Speaker: *Charles Marmar, USA*

 10.00 – 12.00

S-14 ▶ Symposium

Topic: Pharmacogenetics/Pharmacokinetics

Track: Clinical

Pharmacogenomics and personalised medicine in psychiatry: Prospects for clinical implementationChair: *Bernard Lerer, Israel***Genomics of response and side effects of antipsychotics***Dan Rujescu, Germany***Pharmacogenetics of antidepressant therapies***Alessandro Serretti, Italy***Pharmacogenomics of nicotine addiction***Bernard Lerer, Israel***The role of leptin in the pharmacogenomics of obesity***Ma-Li Wong, Australia*

Preliminary Scientific Programme

Tuesday, 5 June 2012

10.00 – 12.00

S-15 ► Symposium

Topic: Molecular Neurobiology/Pharmacology
Track: Clinical

Oxytocin in normal and abnormal psychology: Promises and caveats

Chair: *Martin Brüne, Germany*

Oxytocin increases the salience of social agents: Evidence from psychopathology

Simone Shamay-Tsoory, Israel

Oxytocin treatment in schizophrenia reduces psychotic symptoms and improves theory of mind and social perception

Carsten de Dreu, Netherlands

Oxytocin treatment in schizophrenia reduces psychotic symptoms and improves theory of mind and social perception

Cort Pedersen, USA

Does oxytocin have a role in borderline personality disorder?

Martin Brüne, Germany

10.00 – 12.00

W-03 ► Workshop

Track: Educational

Metabolic syndromes: An update on basic mechanisms and clinical care

10.00 – 11.00

D-03 ► Pro and Con Debate

Track: Educational

Are second generations superior to first generation antipsychotics?

11.00 – 12.00

D-04 ► Pro and Con Debate

Track: Educational

Is polypharmacy necessary to achieve good treatment results?

14.00 – 14.45

PL-04 ► Plenary Lecture

Topic: Cognition in Psychiatry

Psychopharmacology and Cognition

Speaker: *Barbara Sahakian, United Kingdom*

15.00 – 17.00

S-16 ► Symposium

Topic: Dementia
Track: Translational

Alpha7 nicotinic acetylcholine receptors in dementia and other brain disorders: From bench to bedside

Chair: *Peter Brust, Germany*

Alpha7 acetylcholine receptor-lipid crosstalk in health and dementia

Francisco Barrantes, Argentina

Alpha7 nicotinic receptors as important targets for neuroprotective mechanisms in new drug targets for Alzheimer's disease

Agneta Nordberg, Sweden

Neuronal circuits and mechanisms involved in the cognitive enhancing properties of $\alpha 7$ nicotinic acetylcholine receptor (nAChR) modulators

Jens Mikkelsen, Denmark

Alpha7 nicotinic acetylcholine receptors as a potential target for imaging of brain disorders with Positron Emission Tomography

Peter Brust, Germany

15.00 – 17.00

S-17 ► Symposium

Topic: Childhood & Adolescent Disorders
Track: Translational

Neurodevelopmental bases for progress in pharmacotherapy in autism spectrum disorders

Chair: *Kunio Yui, Japan*

Neurophysiological biomarker of impaired social interaction in ASD

Kunio Yui, Japan

The predictive value of multiparameter image of whole-brain structures in autism spectrum disorders

Christine Ecker, United Kingdom

Serum biomarker patterns in ASD

Emanuel Schwarz, United Kingdom

Mapping early brain development in ASD

Eric Courchesne, USA

Preliminary Scientific Programme

 Tuesday, 5 June 2012

15.00 – 17.00

S-18 ► Symposium

Topic: Depression

Track: Translational

Fatigue syndrome in psychiatry. Novel understanding and treatmentsChair: *Siegfried Kasper, Austria***The psychiatrist confronted with a chronic fatigue/fibromyalgia patient***Siegfried Kasper, Austria***Treating CFS – it may not be rocket science, but at least it works***Simon Wessely, United Kingdom***The concept of 'Mental Fatigue' in a broader dimensional context***Carol Tamminga, USA***Effect of the dopamine stabilizer OSU 6162 on mental fatigue in neurological patients***Arvid Carlsson, Sweden*

15.00 – 17.00

S-19 ► Symposium

Topic: Schizophrenia

Track: Translational

Recent advances in research on serotonergic hallucinogens: Implications for treatment of schizophreniaChair: *Franz X Vollenweider, Switzerland***Hallucinogenic signaling in a GPCR heterocomplex***Javier González Maeso, USA***Pharmacological and genetic animal models of serotonergic contributions to schizophrenia and its treatment***Mark Geyer, USA***Hallucinogens suppress slow cortical oscillations in thalamocortical circuits. Reversal by antipsychotic drugs***Francesc Artigas, Spain***Imaging, physiological and cognitive studies of serotonergic model psychosis in humans***Franz X Vollenweider, Switzerland*

15.00 – 17.00

S-20 ► Symposium

Topic: Molecular Neurobiology/Pharmacology

Track: Translational

The translocator protein (18 KDa) as a novel target in neurology and psychiatryChair: *Rainer Rupprecht, Germany***Translocator protein 18 kDa ligands as novel anxiolytics without benzodiazepine like side effects***Rainer Rupprecht, Germany***Structure and function of translocator protein (18 kDa)***Vassilios Papadopoulos, Canada***Using PET to explore the role of the translocator pattern in human brain diseases***David Nutt, United Kingdom***Peripheral nerve regeneration: Therapeutic perspectives for TSPO ligands***Michael Schumacher, France*

15.00 – 17.00

S-21 ► Symposium

Topic: Antidepressants

Track: Translational

From gene to drug response: Multi-method approach to the pharmacogenomics of response to antidepressantsChair: *Katherine Tansey, United Kingdom***Multi-method approaches to pharmacogenomics in animal models***Maurizio Popoli, Italy***Transcriptomic and epigenetic correlates of antidepressant response***Gustavo Turecki, Canada***Antidepressants and emotional processing***Catherine Harmer, United Kingdom***Genomic search for predictors of antidepressant response: Is there more information in the phenotype?***Katherine Tansey, United Kingdom*

Preliminary Scientific Programme

Tuesday, 5 June 2012

15.00 – 17.00

S-22 ► Symposium

Topic: Electroconvulsive Therapy
Track: Clinical

ECT: Research and practice update

Chair: Charles Kellner, USA

What we now know about ECT mechanisms of action

Tom Bolwig, Denmark

Latest NIMH supported ECT data – efficacy and safety

Charles Kellner, USA

Impact of ECTAS on UK ECT

Chris Freeman, United Kingdom

Cognitive effects of ECT

Declan McLoughlin, Ireland

Wednesday, 6 June 2012

09.00 – 09.45

PL-05 ► Plenary Lecture

Topic: Drug Development

CNS Drug development at present

Speaker: Jeff Conn, USA

10.00 – 12.00

S-23 ► Symposium

Topic: Antipsychotics
Track: Translational

Defining the neurobiological basis of cognitive impairment in schizophrenia through translational research

Chair: Herbert Meltzer, USA

Serotonergic-glutamatergic-dopaminergic interactions: The basis for the cognitive enhancing effects of atypical antipsychotic drugs in schizophrenia and NMDA receptor antagonist animal models

Herbert Meltzer, USA

Pharmacological means to improve cognition in schizophrenia and bipolar disorder by activation of cortical dopamine D1 receptors and NMDA receptor-mediated transmission

Torgny Svensson, Sweden

Translational biomarkers of NMDA dysfunction in schizophrenia: Mechanisms and opportunities

Daniel C Javitt, USA

Neuroimaging and ERP (object completion, MMN) studies into the role of serotonin in psychotic symptom formation and cognitive deficits in human model psychoses

Franz X Vollenweider, Switzerland

10.00 – 12.00

S-24 ► Symposium

Topic: Psychoneuroimmunology
Track: Translational

Cytokines and psychiatric illness

Chair: Göran Engberg, Sweden

Inflammation-induced depression: Evidence and mechanisms

Robert Dantzer, USA

Cytokines as a cause of suicidality?

Lena Brundin, Sweden

Neuroinflammation in psychotic disorders

Göran Engberg, Sweden

Cytokines in psychiatric disorders: Therapeutic approaches

Norbert Müller, Germany

10.00 – 12.00

S-25 ► Symposium

Topic: Animal Models
Track: Basic

Genetic and non-genetic risk factors in translational models of psychiatric disorders

Chair: Mikhail Pletnikov, USA

Mice mutant for genes associated with schizophrenia: Effects of exposure to biological and psychosocial adversities over developmental trajectory

John Waddington, Ireland

Preliminary Scientific Programme

 Wednesday, 6 June 2012

Infectious and immune factors modulate neurobehavioral abnormalities in DISC1 mice

Mikhail Pletnikov, USA

Identifying interactions between genes and early environment in the mouse

Valeria Carola, Italy

Advanced Paternal Age: Modelling non-genetic risk factors in psychiatry

Darryl Eyles, Australia

 10.00 – 12.00

S-26 ▶ Symposium

Topic: Molecular Neurobiology/Pharmacology

Track: Translational

Emerging opportunities to treat psychiatric disorders with muscarinic receptor agonists

Chair: *Elizabeth Scarr, Australia*

Is there evidence to suggest that muscarinic receptors are viable targets for the treatment of schizophrenia?

Elizabeth Scarr, Australia

Muscarinic receptors in the pathophysiology

Brian Dean, Australia

Genetic variation in cholinergic muscarinic 2 receptor gene accounts for reduced binding in bipolar disorder

Dara Cannon, Ireland

Potential roles for allosteric muscarinic receptor modulators for the treatment of psychiatric and neurologic disorders

Carrie Jones, USA

 10.00 – 12.00

S-27 ▶ Symposium

Topic: Depression

Track: Translational

Advances in translational research in serotonin neurobiology: Implications for mood disorders

Chair: *Xiohua Li, USA*

Molecular target of serotonin neurotransmission – implication in therapeutics of mood disorders

Xiohua Li, USA

Role of the serotonin receptor adaptor protein p11 in depression

Per Svenningsson, Sweden

Contribution of animal models to understanding epigenetic mechanisms in affective disorders and resilience

Klaus Peter Lesch, Germany

Molecular imaging of serotonin vulnerability in mood disorders

Gwenn Smith, USA

 10.00 – 12.00

W-04 ▶ Workshop

Topic: Premenstrual Syndrome

Track: Educational

Premenstrual dysphoric disorder: An update

 10.00 – 11.00

D-05 ▶ Pro and Con Debate

Track: Educational

Is augmentation better than switching in the treatment of depression?

 11.00 – 12.00

D-06 ▶ Pro and Con Debate

Track: Educational

Are SSRI's not having clinically relevant efficacy?

 14.00 – 14.45

PL-06 ▶ Plenary Lecture

Topic: Depression

Rational pharmacotherapies of major depressive disorder

Speaker: *Siegfried Kasper, Austria*

 15.00 – 17.00

S-28 ▶ Symposium

Topic: Schizophrenia

Track: Translational

Novel targets for antipsychotic medication development

Chair: *Anthony Grace, USA*

Modulation of hippocampal GABA A alpha 5 receptors reverses pathophysiology in rodent model of schizophrenia

Anthony Grace, USA

10A (PDE10A) inhibitors for treatment of schizophrenia

Jacob Nielsen, Denmark

The glycine reuptake inhibitor (GRI) bitopertin: Going beyond antipsychotics towards a non-dopaminergic treatment for schizophrenia

Daniel Umbricht, Switzerland

Preliminary Scientific Programme

Wednesday, 6 June 2012

Modulation of glutamate function via mGluR5 and T type calcium channels: Potential novel antipsychotic targets?

Peter Hutson, USA

15.00 – 17.00

S-29 ► Symposium

Topic: Depression

Track: Translational

Molecular and genetic substrates underpinning diagnosis of major depression

Chair: Yogesh Dwivedi, USA

Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with Major Depression

Etienne Sibille, USA

Identifying differentially methylated regions in depression and suicide by next generation sequencing

Gustavo Turecki, Canada

Role of MicroRNAs in depression: Evidence from animal and human postmortem brain studies

Yogesh Dwivedi, USA

Genome-wide and candidate gene studies for neuroticism

Dan Rujescu, Germany

15.00 – 17.00

S-30 ► Symposium

Topic: Antipsychotics

Track: Clinical

Dosing of Antidepressants and Antipsychotics: Are we doing right?

Chair: Gerhard Gründer, Germany

Central D2-occupancy and optimal dosing – does it apply for atypical antipsychotics?

Lars Farde, Sweden

It's all about the dose – picking doses in drug development

Armin Szegedi, USA

Plasma concentration based dosing of antipsychotics and antidepressants

Christoph Hiemke, Germany

Dosing of antipsychotics and antidepressants: guidance from PET imaging

Gerhard Gründer, Germany

15.00 – 17.00

S-31 ► Symposium

Topic: Mood Stabilisers

Track: Translational

Lithium and novel targets in bipolar disorders

Chair: Janusz Rybakowski, Poland

Interfering with the activating effect of calbindin D28k on inositol mono-phosphatase activity to mimic lithium's inhibitory effect on the enzyme at a different site of action

Galila Agam, Israel

Lithium is a gold standard in bipolar illness. Is it indicated for other conditions?

Martin Alda, Canada

Neurocognition as a lithium target in bipolar disorder

Janusz Rybakowski, Poland

The Consortium on Lithium Genetics (ConLiGen): Genome-wide association studies of lithium response phenotypes in bipolar disorder

Thomas Schulze, Germany

15.00 – 17.00

S-32 ► Symposium

Topic: Molecular Neurobiology/Pharmacology

Track: Translational

Novel NMDA amino acids for the pathophysiology and treatment of mental disorders

Chair: Guochuan Tsai, USA

Novel N-methyl-D-aspartate treatments for mental disorders

Guochuan Tsai, USA

GlyT-1 and DAAO inhibitors as potential therapeutic drugs for schizophrenia

Kenji Hashimoto, Japan

Treatment of NMDA agonist, glycine transporter I Inhibitor and D-Amino acid oxidase inhibitor for mental disorders

Hsien-Yuan Lane, Taiwan

D-Serine, glia-synapse interaction and schizophrenia

Toru Nishikawa, Japan

15.00 – 17.00

W-05 ► Workshop

Track: Educational

Update in the treatment of ADHD in young and adults

Preliminary Scientific Programme

Thursday, 7 June 2012

09.00 – 11.00

S-33 ► Symposium

Topic: Antipsychotics

Track: Translational

Do psychotropics affect brain structure? Linking animal models, imaging and clinical studiesChair: *Shitij Kapur, United Kingdom***Contrasting effects of antipsychotics and lithium on the brain: In-vivo MRI and ex-vivo confirmation***Shitij Kapur, United Kingdom*Speaker: *Nancy Andreasen, USA***Drugs, stress and inflammation: Explaining structural brain changes in schizophrenia***Christos Pantelis, Australia***Lithium effects on brain gray matter volumes***Perry F Renshaw, USA*

09.00 – 11.00

S-34 ► Symposium

Topic: Imaging

Track: Clinical

Molecular imaging biomarkers in major CNS diseases and drug developmentChair: *Gerhard Gründer, Germany***Translational prediction and validation of imaging biomarkers***Tetsuya Suhara, Japan***Amyloid imaging: A boost for drug development***Koen van Laere, Belgium***Imaging biomarkers in substance abuse***Gerhard Gründer, Germany***Novel PET biomarkers for dementia and psychosis and target engagement – Cannabinoids, metabotropic glutamate, and beyond***Dean F. Wong, USA*

09.00 – 11.00

S-35 ► Symposium

Topic: Depression

Track: Clinical

Advances in understanding the causes and treatment of major depressive disordersChair: *Hans-Jürgen Möller, Germany***The role of tumour necrosis factor in the pathophysiology of major depressive disorders and bipolar disorders***Andrew Gibbons, Australia***The neuroanatomy of melancholy: An update circa 2012***Jair Soares, USA***Animal models of depression: Relevance to drug discovery***Trevor Norman, Australia***How to improve treatment strategies in depression***Hans-Jürgen Möller, Germany*

09.00 – 11.00

S-36 ► Symposium

Topic: Addictive Disorders

Track: Clinical

Drug targets and novel treatment strategies in alcohol and drug addictionChair: *Falk Kiefer, Germany***Development of new medications for the treatment of alcoholism***Charles O'Brien, USA***The role of the GABAB receptor system in alcoholism and stress: The role of the GABAB receptor agonist baclofen***Giovanni Addolorato, Germany***Impact of the stress hormone system as a pharmacotherapeutic target in the treatment of alcohol and drug addiction***Falk Kiefer, Germany***ADHD in drug addiction: a randomized-controlled trial on the efficacy of methylphenidate in criminal amphetamine users***Johan Franck, Sweden*

Preliminary Scientific Programme

Thursday, 7 June 2012

09.00 – 11.00

S-37 ► Symposium

Topic: Animal Models

Track: Basic

Stress and vulnerability – antecedents to psychopathology and implications for effective treatmentChair: *David Morilak, USA***Early life adverse experience, 5-HT₂ receptors and long term epigenetic modifications: Implications for affective vulnerability**Vidita Vaidya, *India***Social isolation stress in a genetic rat model of depression: Effects of physical activity as an intervention**Stefan Brené, *Sweden***Mouse model of vulnerability to emotional trauma: Neural correlates and novel treatment options**Nicolas Singewald, *Austria***Chronic stress, dysregulation of prefrontal cognitive function and mechanisms underlying the response to effective antidepressant treatment**David Morilak, *USA*

09.00 – 11.00

S-38 ► Symposium

Topic: Deep Brain Stimulation

Track: Clinical

Neurostimulation therapies: Current advances and controversiesChair: *Sidney Kennedy, Canada*Speakers: *Ziad Nahas, USA**Thomas Schlaepfer, Germany**Sidney Kennedy, Canada*

09.00 – 11.00

W-06 ► Workshop

Topic: Sleep Disorders

Track: Educational

Update in the treatment of sleep disorders

11.15 – 12.00

PL-07 ► Plenary Lecture

Topic: Alzheimer's

Drugs for Alzheimer's diseaseSpeaker: *Bengt Winblad, Sweden*

This is a Preliminary Programme and is subject to changes. Please refer to the Congress website, www.cinp2012.com, for an up-to-date programme.

Call for Poster Abstracts

Submission of Poster Abstracts

Participants are invited to submit abstracts for poster presentations. These should give a brief description of the title and topic.

All abstracts will be assessed by members of the International Scientific Programme Committee. The assessors will judge the abstracts according to the relevance to CINP, standard of English, objectivity of statement, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall impression. All accepted abstracts will be published in the online International Journal of Neuropsychopharmacology (IJNP) and online on the congress website: www.cinp2012.com

Please visit the Congress website www.cinp2012.com for detailed instructions regarding the electronic submission of abstracts.

The deadline for poster submission is **31 January 2012**

Guidelines for Submission

- Abstracts must be submitted in English.
- The successful participant is committed to present their poster at the designated time slot allocated to them by the International Scientific Programme Committee.
- Changes in authorship should be communicated to the International Scientific Programme Committee in order to ensure correct appearance in the printed programme until 13 April 2012: cinp2012@cpo-hanser.de
- If the original presenting author is unable to present, one of the co-authors should take over this responsibility.
- When participants are submitting a poster abstract, they must submit a completed registration form and payment of the correct registration fee must be received by the congress and exhibition office CPO HANSER SERVICE no later than 31st January 2012.
- If the poster is not accepted the delegate will have the right to a full registration refund.

We encourage submitting authors to register via the online registration system along with the abstract submission.

The acceptance of abstracts by the International Scientific Programme Committee does not imply any financial assistance or fee reduction.

Notification of acceptance or rejection by the International Scientific Programme Committee will be emailed to the presenting author.

Detailed information, guidelines and recommendations for poster presentation, as well as time allocation, date, hour, and venue will be sent in due time to registered presenting authors.

Guidelines for Preparation of Abstracts

Please choose a title that clearly indicates the content of the contribution. Please avoid abbreviations in the title. Abbreviations may be used in the text if they are defined when used first. A maximum of 300 words is allowed.

The author's name (full first name, family name) and place of work (institution, city, country) should be indicated. Degrees, titles, street addresses and acknowledgements of support should be omitted, however.

To provide maximum information in the abstract please

- state the specific objective of the study
- state the methods used, if pertinent
- summarize the results obtained
- state the conclusions reached

Please ensure that the abstract does not contain spelling, grammar or scientific errors, as it will be reproduced exactly as submitted.

Please submit a poster which is relevant to the conference topic.

Please note: Cambridge University Press (CUP) is the publishing house of the International Journal of Neuropsychopharmacology (IJNP). CUP recommendations "How to publish an abstract" can be found on the congress website. Please consider also these guidelines: www.cinp2012.com/abstracts

Poster Sessions

Poster sessions will be held from Monday 4 June to Wednesday 6 June 2012. These sessions offer an interactive forum for the exchange of information and a means to communicate ideas, research, and programmes.

Poster authors must attend these sessions to give feedback to conference attendees who stop by to ask questions. At this congress, posters will be grouped by topics for the convenience of those attending the sessions.

Poster Awards

Clinical, translational, and basic neuroscience research awards are given. Those presenting the best posters receive a certificate. These awards serve to encourage young scientists (under 35) who are actively involved in clinical and pre-clinical research. The final selection of Poster Awards will be made on the basis of the study's scientific excellence.

Application for Poster Awards

To be eligible for a poster award, the applicant must check the applicable box on the online poster submission form at: www.cinp2012.com.

Call for Poster Abstracts

Topics

When submitting an abstract, please choose one of the following topics:

1. Addictive disorders
2. Animal Models
3. Antidepressants
4. Antipsychotics
5. Anxiety disorders
6. Anxiolytics
7. Attention deficit disorders
8. Bipolar disorders
9. Deep brain stimulation
10. Childhood & Adolescent disorders
11. Dementia
12. Depression
13. Eating disorders
14. Epilepsy
15. Ethics of Psychopharmacology
16. Genetics
17. History of Psychopharmacology
18. Hypnotics
19. Imaging
20. Molecular Neurobiology/Pharmacology
21. Mood stabilisers
22. Neuropathology/Post mortem studies
23. Neurophysiology
24. Obsessive-Compulsive disorders
25. Pain
26. Panic disorders
27. Personality disorders
28. Pharmacoeconomics
29. Pharmacogenetics/Pharmacokinetics
30. Post Traumatic stress disorders
31. Premenstrual syndrome
32. Psychoneuroimmunology
33. Schizophrenia
34. Sexual disorders
35. Sleep disorders
36. Suicide
37. Tobacco Dependence
38. Transcultural Psychopharmacology



Photographs © Stockholm Visitors Board

Brief Biography of Plenary Speakers



Hans-Jürgen Möller, Germany
Monday, 4 June 2012, 09.00 – 09.45 h

Schizophrenia: Course, causes and developments in drug treatment

Hans-Jürgen Möller has been working in the field of psychiatry for 30 years. After obtaining his Doctor of Medical Science in 1972 from the Universities of Göttingen and Hamburg, Germany, he then specialised in psychiatry and postgraduate training at the Max Planck Institute of Psychiatry in Munich. Professor Möller completed a postdoctoral thesis (habilitation) in psychiatry in 1979. From 1980 to 1988 he was professor of psychiatry at Munich Technical University, and from 1988 to 1994 full professor of psychiatry and chairman of the Psychiatric Department at the University Bonn, Bonn, Germany. He is currently full professor of psychiatry and chairman of the Psychiatric Department at the Ludwig-Maximilians-University, Munich.

Professor Möller's main scientific contributions include clinical and neurobiological research into psychiatry, schizophrenia and depression and clinical psychopharmacology. He has been a member of the executive committees of several national and international psychiatric societies. He is the past president of the European Psychiatric Association (EPA). He serves as chairman of the Section on Pharmacopsychiatry of the World Psychiatric Association (WPA). For four years he has been a member of the executive committee of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), where he is now President. From 1997 to 2001 he was president of the World Federation of Societies of Biological Psychiatry (WFSBP), where he is now honorary president.

In addition to authoring and co-authoring over 1100 publications such as original articles, international papers and several books (Hirsch-Factor 56), he has acted as chief editor of *The World Journal of Biological Psychiatry* from 2000 to 2009. He is main editor of *European Archives of Psychiatry and Clinical Neuroscience*, and editor of two major German psychiatric journals, *Nervenarzt* and *Psychopharmakotherapie*. He holds positions on the editorial boards of numerous national and international psychiatric journals.

In 2008, Professor Möller was awarded the prestigious Jean Delay Prize from the World Psychiatric Association. In 2009, he was awarded the honorary doctorate by the University Victor Babes of Timisoara/Hungary, the WFSBP Lifetime Achievement Award and the Aristotle Medal by the University of Thessaloniki



Nora Volkow, USA
Monday, 4 June 2012, 14.00 – 14.45

Addiction: from molecules to neuronal circuits

Dr. Volkow became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world's research on the health aspects of drug abuse and addiction.

Her work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects of drugs and their addictive properties. Her studies have documented long lasting changes in the dopamine system affecting the actions of frontal brain regions involved with motivation, reward and inhibitory control in drug addicted subjects. She has also made important contributions to the neurobiology of obesity, ADHD, and the behavioral changes that occur with aging.

Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Premio Robins award for best medical student of her generation. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA.

She spent most of her professional career at the Department of Energy's Brookhaven National Laboratory (BNL) in Upton, New York, where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.

Dr. Volkow has published more than 495 peer-reviewed articles and more than 65 book chapters and non-peer reviewed manuscripts, and has also edited three books on the use of neuroimaging in studying mental and addictive disorders.

During her professional career, she has been the recipient of multiple awards, including her selection for membership in the Institute of Medicine in the National Academy of Sciences. She was recently named one of Time Magazine's "Top 100 People Who Shape our World", and was included as one of the 20 people to watch by Newsweek magazine in its "Who's Next in 2007" feature. She was also named "Innovator of the Year" by U.S. News & World Report in 2000.



Pasko Rakic, USA

Tuesday, 5 June 2012, 09.00 – 09.45 h

Depressing tales of adult neurogenesis: a hard look at the evidence

Pasko Rakic, MD, PhD, received his medical and graduate degrees in developmental biology and genetics from Belgrade University (former Yugoslavia), where he became Assistant Professor until being offered a faculty position at Harvard Medical School, where he stayed 8 years before taking the endowed Duberg professorship at Yale University where he is presently Chairman of the Department of Neurobiology and Director of the Kavli Institute for Neuroscience.

Dr. Rakic's research interests are in developmental neurobiology, particularly cellular and molecular mechanisms of neuronal proliferation, migration and synaptogenesis during development and evolution of the cerebral and cerebellar cortex. His studies lead to the postulate of the "radial unit" and "protomap" hypotheses of cortical development and evolution that provide the framework for understanding of normal and pathological development of the human brain. By manipulating the rate and pattern of neuronal migration, using genetic tools and environmental factors, he with his colleagues discovered the hidden abnormalities of neuronal positioning that cannot be discerned by routine postmortem examination of the human brain, providing explanations for the pathogenesis of a variety of congenital malformations including lissencephaly, polymicrogyria and childhood epilepsy, as well as new insight into possible developmental origin of disorders of higher brain functions, such as autism, schizophrenia and forms of mental retardation.

Dr. Rakic is a member of the National Academy of Sciences (USA); American Academy of Arts and Sciences, Institute of Medicine (USA), and foreign member of Norwegian Academy of Science and Letters, Serbian Academy of Sciences and Croatian Academy of Arts Sciences. He has also been President of the Society for Neuroscience. His honors include Karl Spencer Lashley Award, Francois I Medal, College de France, Bristol-Myers Squibb, Pasarow, Henry Gray, Gerard and Fyssen Science Prize, and most recently Kavli Neuroscience Prize for his discoveries on how the neurons in the embryonic brain arrange themselves during development into the complex, densely interconnected synaptic circuitry of the adult cerebral cortex.



Barbara Sahakian, United Kingdom

Tuesday, 5 June 2012, 14.00 – 14.45 h

Psychopharmacology and Cognition

Barbara J Sahakian is Professor of Clinical Neuropsychology at the University of Cambridge Department of Psychiatry, and the Medical Research Council/Wellcome Trust Behavioural and Clinical Neuroscience Institute. She is also a Clinical Psychologist.

She has an international reputation in the fields of cognitive psychopharmacology, neuroethics, neuropsychology, neuropsychiatry and neuroimaging. She is co-inventor of the CANTAB computerised neuropsychological tests, which are in use world-wide. She is probably best known for her research work on cognition and depression, cognitive enhancement using pharmacological treatments, neuroethics and early detection of Alzheimer's disease. Indeed, she has over 350 publications covering these topics in scientific journals, including Science, Nature, Nature Neuroscience, The Lancet, British Medical Journal, Archives of General Psychiatry, American Journal of Psychiatry, Biological Psychiatry, the Journal of Neuroscience, Brain, Psychopharmacology and Psychological Medicine. The ISI Web of Science database credits her with a Hirsch (h) Index of 79. Her current programme of research, funded by the Wellcome Trust and Medical Research Council, investigates the neurochemical modulation of impulsive and compulsive behaviour in neuropsychiatric disorders, such as unipolar and bipolar depression and attention deficit hyperactivity disorder. This topic was the focus of her recent papers published in Science, (Chamberlain et al 2006, Chamberlain et al 2008, Chamberlain et al, 2010).

Professor Sahakian was one of the first researchers to suggest that attentional dysfunction in Alzheimer's disease could be ameliorated using pharmacotherapy, such as cholinesterase inhibitors. In addition, she was early to highlight the cognitive changes in unipolar and bipolar depression, as well as their significance for functional outcome. In 2003, she was selected to lecture on this topic for the Teaching Day at the annual meeting of the American College of Neuropsychopharmacology (ACNP). Most recently, she has introduced the importance of the concept of cognitive reserve to the field of neuropsychiatry (Psychological Medicine, 2006, 36, 1053-1064).

In recognition of her contribution to cognitive neuroscience, she was elected a Fellow of the Academy of Medical Sciences in 2004 and in 2005 she was awarded the Donders Chair in Psychopharmacology at Utrecht University (The Netherlands). In 2008 she gave the Deakin Innovation Lectures in

Melbourne, Australia and she was the first woman to give a plenary lecture at ECNP (Barcelona). From 2009 to 2010, she has taken up the Distinguished International Scholars Award at the University of Pennsylvania (USA). In 2010 she was appointed to the Scientific Advisory Board of the Grand Challenges in Global Mental Health (<http://grandchallengesgmh.nimh.nih.gov/>). She is on the Steering Group for the Royal Society Brain Waves Project which is currently launching a series of reports on developments in neuroscience and their implications for society and policy (<http://royalsociety.org/brainwaves/>). She has recently been appointed to the Council of CINP and is President-Elect of the British Association for Psychopharmacology. She was honoured with the Senior Investigator Award from ICGP (2010). In 2011 she gave the Royal Society of Medicine's Henry Barnes Lecture on cosmetic enhancement and the plenary lecture at the Scandinavian College of Neuropsychopharmacology annual meeting. Later on in the year she will be giving the BBR/Elsevier Prize Lecture at the EBBS meeting in Seville, Spain as well as the Otto Wolf Lecture at the UCL Institute of Child Health and Great Ormond Street Hospital.

She has keen interests in women in neuroscience, neuroethics, engagement of the public in science and neuroscience and mental health policy. From November 2005 she began a three-year appointment to the Committee of Women in Neuroscience for the Society for Neuroscience (SFN, USA). In 2010 she gave the Women in Neuroscience Luncheon Lecture at the Society for Neuroscience Annual Meeting (http://www.sfn.org/index.aspx?pagename=womeninneuroscience_luncheon). In 2006 she began her appointment on the Medical Research Council (MRC) Neurosciences and Mental Health Board and in 2008 she was appointed to the MRC Expert Group for Strategy on Mental Health. She was a founder member and was appointed to the Executive Committee of the Neuroethics Society and is on the Editorial Board of the American Journal of Bioethics – Neuroscience. She has co-edited of The Oxford Handbook of Neuroethics (2011). She frequently engages with the public on areas of neuroscience and neuroethics, and has given the Nature Debate (2008) and the Royal Society President's Lecture (2009). She has an Academic Attachment to the Uehiro Centre for Practical Ethics at the University of Oxford.

In 2006 she was appointed as a member of the Science Co-ordination Team for the Foresight Project on Mental Capital and Wellbeing (UK Office of Science, Department of Innovation, Universities and Skills). (www.foresight.gov.uk). This project was launched in October 2008 (Beddington et al 2008 Nature). More recently, she has contributed to the MRC Review of Mental Health Research Report of the Strategic Review Group 2010 (Sahakian et al, 2010, The Lancet). In 2011 she was appointed a member of the Steering Committee for the Joint Academies project on human enhance-

ment in the workplace (Joint Academies: The Academy of Medical Sciences, British Academy, The Royal Academy of Engineering, The Royal Society)

Professor Sahakian has also trained over 20 PhD students in the field of cognitive neuroscience, many now with international reputations in their own right (e.g. Adrian M Owen, Rebecca Elliott, Andrew D. Lawrence, Adam Aron) and several prize winners (e.g. Jennifer Coull, Mitul Mehta, Danielle Turner, Samuel Chamberlain). Since 2004 she has been writing and training PhD students in the field of neuroethics. One of her students, Danielle Turner, who completed her PhD on the psychopharmacology of cognitive enhancement in 2005, received an award from the British Psychological Society and was recently selected as one of the top five young UK researchers. Her PhD student, Karen Ersche, was recently appointed Betty Behrens Research Fellow at Clare Hall, Cambridge.

Professor Sahakian is a Fellow of Clare Hall and Bye-Fellow of Christ's College.



Jeff Conn, USA

Wednesday, 6 June 2012, 09.00 – 09.45 h

CNS Drug Development at present

Dr. Conn is the Lee E. Limbird Professor of Pharmacology at Vanderbilt University and Director of the Vanderbilt Center for Neuroscience Drug Discovery. Dr. Conn received the Ph.D. degree in Pharmacology from Vanderbilt in 1986 and pursued postdoctoral studies at Yale University. Dr. Conn joined the faculty of the Department of Pharmacology at Emory University in 1988 where he established himself as a leader in studies of neurotransmitter receptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. In 2000, Dr. Conn assumed the position of Senior Director and Head of the Department of Neuroscience at Merck and Company in West Point, PA. Dr. Conn moved to Vanderbilt University in 2003 as the founding director of the Vanderbilt Program in Drug Discovery (VPDD), with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics.

By 2011 the VPDD had grown to approximately 100 full time scientists and raised over \$80M in research funding. In addition, the VPDD advanced novel molecules from three major programs into development for clinical testing in major brain disorders with industry partners. A fourth program reached development status and is advancing internally at Vanderbilt. To mark this growth and facilitate

more fluid integration of drug discovery, development, and corporate partnerships, the VPDD achieved independent center status and was named the Vanderbilt Center for Neuroscience Drug Discovery in January 2011. Dr. Conn is Editor in Chief of Molecular Pharmacology, Regional Editor (North America) of Current Neuropharmacology and serves on the editorial boards of 6 other international journals. He has served the Scientific Advisory Boards of multiple foundations and companies in the pharmaceutical and biotech industries.

He currently serves as the founding director of the scientific advisory board of Karuna Pharmaceuticals and on the advisory boards of Seaside Therapeutics and the Michael J. Fox Foundation. He served as Chairman of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET) and on multiple national and international committees.

He has received numerous awards, including the NARSAD Essel Distinguished Investigator Award, the ASPET-Astellas Award in Translational Pharmacology, the Pharmacia – ASPET Award for Experimental Therapeutics, the Charles R. Park Award for Basic Research Revealing Insights into Physiology and Pathophysiology, the PhRMA Foundation Award for Excellence in Pharmacology and Toxicology. He was named as an ISI Most-Cited Scientists in Pharmacology & Toxicology and the Lee University 2008 Distinguished Alumnus of the Year.

Dr. Conn's current research is focused on development of novel treatment strategies for schizophrenia, Parkinson's disease, and other serious brain disorders.



Siegfried Kasper, Austria
Wednesday, 6 June 2012, 14.00 – 14.45 h

Rational pharmacotherapies of major depressive disorder

Dr Siegfried Kasper is Professor of Psychiatry and Chairman of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. Born in Salzburg, Austria, he was educated at the medical schools of the University of Innsbruck, Austria and the Universities of Freiburg and Heidelberg, Germany. Dr Kasper gained clinical and research experience in psychiatry at the Central Institute of Mental Health, Mannheim, Germany, the Psychiatric Department of the University of Heidelberg, Germany, the Clinical Psychobiology Branch of the National Institute of Mental Health, Bethesda, Maryland/USA, and

the Psychiatric Department of the University of Bonn, Germany; in neurology at the Neurological Department of the University of Heidelberg in Mannheim; and psychotherapeutic and psychoanalytic training at the Ausbildungsinstitut für Psychotherapie und Psychoanalyse in Heidelberg/Mannheim, Germany.

Dr. Kasper published 794 in ISI (<http://portal.isiknowledge.com>) listed publications (Citation Index: 8256, Hirsch-Index: 47) and more than 200 book chapters, in various areas of psychiatry. He concentrates on the biological bases of mental disorders and their possible treatment approaches. Furthermore, he has conducted studies in psychopathological as well as clinical areas. Dr Kasper is a frequent national and international speaker and continues to be actively involved in research programmes studying depression, anxiety, psychosis, and dementia.

Dr Kasper serves on the executive committees and advisory boards of several national and international societies, such as the European College of Neuropsychopharmacology (ECNP) and the Collegium Internationale Neuro-Psychopharmacologicum (CINP). He is Founding President of the Austrian Society of Drug Safety in Psychiatry (ÖAMSP) and of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry (ÖGPB). Furthermore, he is an Honorary Member of the Czech and Romanian Societies of Neuropsychopharmacology, the Hungarian Psychiatric Association and a Fellow of the Royal College of Psychiatrists, UK, as well as of the Ukrainian Association of Psychiatry. Furthermore, he has been appointed Honorary Professor at the University of Hong Kong, China in 2005. In 1997, he was President of the 10th ECNP Congress, was Chairman of the Local Organizing Committee of the WPA Thematic Conference in 2004 and Co-Chair of the Local Organizing Committee of the WFSBP Congress 2005 and in 2007 Local Advisor for the ECNP congress in Vienna. In 2009, he was President of the WFSBP Congress in Paris. From 2005 to 2009 Dr. Kasper was President of the World Federation of Societies of Biological Psychiatry (WFSBP).

Dr Kasper serves on the editorial boards of numerous learned journals (total 51), including Journal of Clinical Psychiatry, CNS Spectrums, Journal of Affective Disorders, Pharmacopsychiatry, European Archives of Psychiatry and Neuroscience. He is Chief-Editor of the World Journal of Biological Psychiatry, Co-Editor-in-Chief of the International Journal of Psychiatry in Clinical Practice, and Field Editor of the International Journal of Neuropsychopharmacology.

As a result of his research expertise he is the recipient of numerous national and international scientific and public awards and prizes and has recently been acknowledged with the Commander's Cross 1st class of the Republic of Austria.

**Bengt Winblad, Sweden**

Thursday, 7 June 2012, 11.15 – 12.00 h

Drugs for Alzheimer's Disease

Professor Bengt Winblad, MD, PhD has been involved in the field of dementia research for many years. After pre-clinical medical studies in Vienna, Austria, he became MD 1971 and took his PhD in 1975 at Umeå University, Sweden, where he became a Docent in 1977 and Professor of Geriatric Medicine and Chief Physician in 1982. Bengt Winblad has been a guest professor at the Department of Psychiatry in Frankfurt and appointed honorary professor at Beijing University, Wuhan University and Shanghai University in China. Since 1987, he is working in Stockholm, Sweden as Professor of Geriatric Medicine at the Karolinska Institutet and is Chief Physician at Karolinska University in Huddinge.

Professor Winblad is co-chairing the European Alzheimer Disease Consortium (EADC) and chairing the Medical Scientific Advisory Panel of the Alzheimer Disease International (ADI). He is the Head of the KI-Alzheimer Disease Research Center in Huddinge including KASPAC (KI Dai-nippon Sumitomo Alzheimer Center), as well as the Director of the Swedish Brain Power research network.

Bengt Winblad's research interests focus on the epidemiology, genetics and treatment of Alzheimer's disease. He has been presented with a number of awards for his contribution to this research area, which have included the Swedish Society of Medicine Alzheimer Award, the Royal Swedish Academy of Medical Sciences Award, the Alois Alzheimer Award, the Swedish Society of Medicine Award and the IPA Recognition Award for Service to the Field of Psychogeriatrics. He has taken the initiative regarding pharmaceutical treatment of patients with severe Alzheimer's disease. Professor Winblad has been a tutor for more than 150 PhD dissertations and has published more than 1000 original publications in the field of gerontology/geriatrics/dementia research.

Bengt Winblad, together with Khalid Iqbal and Henry Wisniewski, is the founder of the ICAD conferences.

Bengt Winblad was in 2009 ranked the world's most prolific researcher in the Alzheimer field (J Alzheimer's Disease 2009).

CINP Awards

Max Hamilton Memorial Prize

Max Hamilton, M.D., F.R.C.P., F.R.C. Psych., D.P.M. (1912 – 1988) is best known for his assessment of depressive illness through psychometrics. The Hamilton Rating Scale for Depression is widely used throughout the world, and his 1960 paper on the problem of measuring the severity of depression is probably the most cited medical publication in the second half of the twentieth century. The recipient of the 2012 award will be chosen by an international scientific jury by March 2012. This prize consists of a monetary award and an engraved plaque, to be presented at the 28th CINP Congress in Stockholm, Sweden.

CINP Pioneers in Psychopharmacology Award

The Award is given at each Congress to three individuals to honour those who have made major contributions to the field as it has developed. The contributions may be in research, clinical, or administrative areas but must be internationally recognised as significant to the growth of the field. Pioneer Awardees receive round trip air travel and accommodation at the 28th Congress in Stockholm, Sweden, an engraved plaque, paid registration fees and appropriate recognition at the meeting.

Rafaelsen Young Investigators Award

In 1986 Ole Rafaelsen and William Bunney were instrumental in establishing a CINP programme supporting the attendance of young scientists at the 15th CINP Congress in 1986. That programme was posthumously named the Rafaelsen Fellowship Award to honour Dr. Rafaelsen, who died in 1987.

The recipients of the 28th Congress Awards will be chosen by an international scientific jury by early March 2012. A number of Awardees will be selected and presented with Awards consisting of round trip economy air travel, up to four nights accommodation, a certificate, a cash stipend including an element for ground transportation and waived registration fees at the 28th CINP Congress in Stockholm, Sweden.

Nominations for all the awards must be submitted by **Thursday, 5 January 2012** and sent to the CINP Central Office. Please complete and return the appropriate form to apply for the awards.

Judges will make their decision on all applications by early March 2012 and all applicants will be notified of the result with the end of March 2012. Please encourage your colleagues to apply for these awards.

Further details of the CINP awards can be found on the respective application forms in this brochure, please see from page 37.



Congress Registration

Registration and Payment received	until 31 January 2012	until 2 May 2012	after 2 May 2012
CINP Member	EUR 500	EUR 600	EUR 700
Non-Member	EUR 700	EUR 800	EUR 900
Young Scientist*	EUR 300	EUR 350	EUR 400
Delegate from Developing Country**	EUR 200	EUR 220	EUR 240
Student***	EUR 110	EUR 130	EUR 150
Accompanying Person	EUR 90	EUR 90	EUR 90

* Applicants must be under 35 years of age and a copy of passport or other government-issued ID must be forwarded along with the registration.

** Developing Countries: A limited number of developing countries registrations are available. To be eligible, you must reside in one of the following countries, as classified by the World Bank. List see page x.

*** Students aged less than 35 years who are studying for a degree including first degrees, PhD or MD but who have not yet obtained their degree. They must supply a letter from their supervisor or laboratory head to support their application for this reduced fee.

Registration fee for members, non-members, young scientists, delegates from developing countries and students includes:

- ▶ Admission to all scientific sessions
- ▶ Admission to Opening Ceremony
- ▶ Admission to Welcome Reception
- ▶ Admission to poster exhibition and technical exhibition
- ▶ Lunches from Monday to Wednesday
- ▶ Coffee breaks from Monday to Thursday
- ▶ Public transportation passes from Sunday to Thursday
- ▶ Congress materials (delegate bag, final programme)

Registration fee for Accompanying Persons includes:

- ▶ Admission to Opening Ceremony
- ▶ Admission to Welcome Reception
- ▶ Public transportation passes from Sunday to Thursday
- ▶ Half day City Sightseeing "Stockholm Highlights" on Sunday or Monday

Please register online for CINP 2012.

You may also use the enclosed registration form. Should you require additional registration forms, please copy this form. Please return the completed registration form as soon as possible in order to benefit from the lower registration fee by mail or by fax to:

CPO
HANSER[®]
SERVICE

Office Hamburg
Hanser & Co GmbH
PO Box 12 21
22882 Barsbüttel, Germany
Phone: +49-40-670 88 20
Fax: +49-40-670 32 83
Email: cinp2012@cpo-hanser.de

Registrations received after 2 May 2012 will be processed as onsite registrations. Please note that there will be a fee increase after the deadline 2 February 2012.

Invited delegates of sponsoring companies

Scientists sponsored by companies will receive their invitation and a registration voucher directly from the sponsoring company. We kindly ask to return the registration voucher to the congress office.

Sponsoring companies inviting delegates from developing countries shall register their delegates for the full registration fee for members or non-members. The use of the congress fee for developing countries can not be booked by industry companies.

Confirmation

Upon receipt of the registration and the corresponding payment, the congress office will send a confirmation to the participant which also serves as an invoice. Please present this confirmation of registration at the congress counter when picking up your congress material.

Who is Who

Their consent provided, delegates will be given the possibility to have their name, institution, city and country listed in the list of participants published on the internet. Upon request a direct link to the homepage of the participant or his/her institution can be installed.

Congress Registration

Developing Countries

A limited number of developing countries registrations is available. To be eligible, you must reside in one of the following countries, as classified by the World Bank.

Afghanistan	Malawi
Angola	Mali
Armenia	Marshall Islands
Bangladesh	Mauritania
Belize	Micronesia, Fed. Sts.
Benin	Moldova
Bhutan	Mongolia
Bolivia	Morocco
Burkina Faso	Mozambique
Burundi	Myanmar
Cambodia	Nepal
Cameroon	Nicaragua
Cape Verde	Niger
Central African Republic	Nigeria
Chad	Pakistan
Comoros	Papua New Guinea
Congo, Dem. Rep.	Paraguay
Congo, Rep.	Philippines
Côte d'Ivoire	Rwanda
Djibouti	Samoa
Egypt, Arab Rep.	São Tomé and Príncipe
El Salvador	Senegal
Eritrea	Sierra Leone
Ethiopia	Solomon Islands
Fiji	Somalia
Gambia, The	Sri Lanka
Georgia	Sudan
Ghana	Swaziland
Guatemala	Syrian Arab Republic
Guinea	Tajikistan
Guinea-Bissau	Tanzania
Guyana	Timor-Leste
Haiti	Togo
Honduras	Tonga
India	Turkmenistan
Indonesia	Tuvalu
Iraq	Uganda
Kenya	Ukraine
Kiribati	Uzbekistan
Korea, Dem. Rep.	Vanuatu
Kosovo	Vietnam
Kyrgyz Republic	West Bank and Gaza
Lao PDR	Yemen, Rep.
Lesotho	Zambia
Liberia	Zimbabwe
Madagascar	

Payment

When registering for the CINP Congress 2012 please arrange payment of registration fee and any other cost related to the supporting programme. All payments must be made in EUR. We recommend credit card payment. All bank collection fees are the sole responsibility of the registrant.

Credit card (AMEX, Eurocard/Mastercard, VISA)

Bank transfer to the congress bank account:

Hanser & Co w/CINP 2012 ZB
 HSH Nordbank AG
 Account number: 1000 165 432
 Bank code: 210 500 00
 BIC: HSH NDE HH
 IBAN: DE63 2105 0000 1000 1654 32

Cancellation Policy

In case of cancellation, please notify the congress office in writing only:

CPO **HANSER**[®]
 SERVICE

Hamburg Office
 Hanser & Co GmbH
 Zum Ehrenhain 34
 22885 Barsbüttel, Germany
 Email: cinp2012@cpo-hanser.de

A full refund (minus an administrative charge of EUR 100) will be given for cancellations received until 31 January 2012. After 31 January 2012, no refunds will be given.



Photograph © Stockholm Visitors Board

General Information

Congress Venue

Stockholmsmässan, the congress venue, was established in 1946 and is owned by the City of Stockholm and the Stockholm Chamber of Commerce. It is situated in the southwest area of Stockholm.

Stockholmsmässan
Mässvägen 1, Älvsjö
125 80 Stockholm
Sweden



Congress Registration Desk

The congress counter will be located in the entrance hall of the main entrance of Stockholmsmässan.

Preliminary Opening Hours

Sunday, 3 June 2012 ➔ 14:00 – 18:00
Monday, 4 June 2012 ➔ 07:30 – 18:00
Tuesday, 5 June 2012 ➔ 07:30 – 18:00
Wednesday, 6 June 2012 ➔ 07:30 – 18:00
Thursday, 7 June 2012 ➔ 08:00 – 13:00

Congress and Exhibition/Sponsor Office

CPO
HANSER[®]
SERVICE

Office Hamburg
CPO HANSER SERVICE
Hanser & Co GmbH
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49-40-670 882-0
Fax: +49-40-670 32 83
Email: cinp2012@cpo-hanser.de

Poster Exhibition

Posters will be displayed from Monday, 4 June until Thursday, 7 June in Hall A of Stockholmsmässan. The posters will be changed daily and are on display during the opening hours of the technical exhibition. Information regarding poster format, set-up and dismantling will be sent to the authors along with their notification of acceptance.

Technical Exhibition

The 28th CINP World Congress will be accompanied by a major technical exhibition taking place in Hall A of Stockholmsmässan. Potential exhibitors can request an exhibition/sponsoring brochure from the Congress and Exhibition/Sponsor Office, CPO HANSER SERVICE.

Email: cinp2012@cpo-hanser.de

Opening Hours

Monday, 4 June 2012 ➔ 09:00 – 17:00
Tuesday, 5 June 2012 ➔ 09:00 – 17:00
Wednesday, 6 June 2012 ➔ 09:00 – 17:00

Congress Information System: CO CONGRESS ONLINE[®]

For the 28th CINP World Congress 2012, the web based Congress Information System CO CONGRESS ONLINE[®] has been installed: www.cinp2012.com

Prior to the congress CO CONGRESS ONLINE[®] will provide information on:

- ➔ Preparation of the congress
- ➔ List of topics
- ➔ Call for abstracts
- ➔ Faculty
- ➔ Preliminary scientific programme
- ➔ Accepted abstracts
- ➔ Satellite Symposia
- ➔ List of participants (Who is Who)
- ➔ List of exhibitors
- ➔ Supporting programme
- ➔ Level Sponsors and General Sponsors
- ➔ Congress venue
- ➔ City of Stockholm
- ➔ Hotel accommodation
- ➔ Travel to Stockholm
- ➔ Special news
- ➔ Private Mailbox

General Information

Congress Website

Further and updated information will be available on the internet at www.cinp2012.com

Registration, hotel reservation and submission of abstracts are available online.

Congress Language

The official language of the 28th CINP World Congress is English.

Final Programme and Abstracts

The Final Programme and Abstracts will be published on the Internet at CO CONGRESS ONLINE® prior to the congress.

Participants will receive a copy of the final programme with their congress material. Abstracts will be published in the official online journal of CINP, the International Journal of Neuropsychopharmacology

Invitation Letter

The congress will be pleased to send a formal letter of invitation to any individual requesting one. It is understood that such an invitation is intended to help potential delegates to raise funds or to obtain a visa. This does not imply a commitment from the UEGF to provide any financial support. Please request invitation letters from the congress office CPO HANSER SERVICE well in advance but no later than 10 May 2012 as especially during the last weeks before the congress, processing time might vary. The letters will be sent as email attachment. If an express delivery is required, the delegate shall order a courier at his/her own expense.

Visa

The entry formalities for Sweden vary according to the country of origin. Please check the current visa requirements with your travel agent or the local Swedish Consulate in your home country.



Photograph © Stockholm Visitors Board

Hotel Accommodation



© Chetsamba/Fotolia.com

Hotel Reservation via CO CONGRESSHOTEL ONLINE®

CPO HANSER SERVICE is the official housing agency for the 28th CINP World Congress 2012.

Congress and Exhibition Office

CPO HANSER SERVICE

Office Hamburg
CPO HANSER SERVICE
Hanser & Co GmbH
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49-40-670 882-0
Fax: +49-40-670 32 83
Email: cinp2012@cpo-hanser.de

A major number of hotel rooms in different price categories have been reserved in Stockholm and surrounding areas for the 28th CINP World Congress 2012. As a service for individual participants, the Congress and Exhibition Office CPO HANSER SERVICE will arrange your hotel accommodation at no extra charge. There are different hotel room ratings, ranging from 2 to 5 stars.

Hotel Categories

Category	single room min – max	double room min – max
5 star	SEK 3,495 – 4,390	SEK 3,695 – 4,690
4 star	SEK 1,860 – 3,395	SEK 1,960 – 3,595
3 star	SEK 1,290 – 1,950	SEK 1,390 – 2,150

(Exchange rate of EUR 1,00 = SEK 8,73 as per July 2011)

Each category has a minimum and a maximum rate based on single/double occupancy. All hotels offer bath/shower/WC, telephone and breakfast facilities. Hotels of 4 and 5 stars usually have a restaurant and a bar.

All prices (per room, per night) include Swedish VAT at the prevailing rate (12% on room rate, 25% on breakfast) and service charge. Rates are shown for standard rooms. Other types of rooms (superior, deluxe, junior suite etc.) are available on request. These prices are indicative and may be subject to change.

Due to limited room availability in Stockholm, we do advise you to make your reservation as early as possible in order to have the best choice of available hotels.

Hotel accommodation is subject to availability and will be allocated on a "first come, first served" basis. Requests received after 18 May 2012 cannot be guaranteed, although CPO HANSER SERVICE will make every effort to meet participants' requirements.

Hotel reservations can be made online via the online hotel portal CO CONGRESSHOTEL ONLINE® at:
www.cinp2012.com

Reservations by email or telephone will not be accepted. If you have any further questions about accommodation, please contact CPO HANSER SERVICE at:
cinp2012@cpo-hanser.de

Confirmation and Payment

Your reservation is binding for the hotel only if you guarantee the reservation with a credit card. The credit card will not be charged. The hotel bill needs to be paid directly at the hotel upon departure.

Changes and Cancellations

Please address in writing all communication concerning any modifications and cancellations of your reservation to CPO HANSER SERVICE until 21 May 2012. After this date please contact the hotel directly, in writing.

In the event of cancellation before 06 January 2012, the cancellation of the booked hotel room(s) is free of charge. In the event of cancellation/reduction in the number of nights after 06 January 2012, or no-shows, the hotel is entitled to charge the agreed costs to a maximum of the entire booking period to your credit card account. These cancellation policies are only applicable to individual bookings. For information about group bookings and conditions please contact cinp2012@cpo-hanser.de.

Group Reservations

Group reservations (10 rooms minimum) will be handled by separate contracts and separate regulations. For further information please contact CPO HANSER SERVICE directly at cinp2012@cpo-hanser.de.

Information on Stockholm

Stockholm

Stockholm is situated on Sweden's south-central east coast, where Lake Mälaren meets the Baltic Sea. The central parts of the city consist of fourteen islands that are part of Stockholm archipelago and cover an area of about 7,084 square kilometres (2,735 square miles). The geographical city centre is situated on the water, in the bay Riddarfjärden. Over 30 % of the city area is made up of waterways. Around 40 % of the territory consists of parks or recreational areas and there are seven nature preserves within city limits which are all easily reachable by public transportation.

Airport and Arrival Information

Stockholm-Arlanda is Sweden's largest airport and an important hub for both the Stockholm region and Scandinavia – primarily thanks to aviation, with 167 destinations around the world provided by over 80 airlines, but also due to its good ground transport services to and from other parts of the Stockholm region.

Transport between the Airport and the City/Local Transportation

The fastest and easiest way to get to the city is by the Arlanda Express (train), which takes 20 minutes or even less from Arlanda airport. Due to good road connections for taxis and bus lines and thanks to long-distance trains and commuter trains, which go both ways from and to the airport, the city is easily accessible.

With its fourteen islands Stockholm is geographically unique. The area also covers a distance of several kilometres outside the actual city centre. Whether by taxi, Metro, commuter trains, suburban railways, ships or hundreds of bus lines, you can get to know the city easily and gain impressions of one of the world's most beautiful capitals.

Metro

The metro runs to all central areas of the city and has station entrances in the most tourist areas. They are marked with the letter "T". It runs from 05:00 to 01:00, Monday to Friday and extended all night service on weekends.



Photograph © Stockholm Visitors Board

Taxi

Most people prefer to use taxis at night for speed and comfort. Taxis are available at any time. There are many taxi companies to choose from in Stockholm. Approved taxis with metered fares always carry yellow number plates. You can easily get hold of a taxi by calling a taxi company, hailing one on the street or by taking one from a rank.

There is a manned taxi centre at Central Station that can help you with finding the right service, e.g. if you need child seats in the vehicle. Metered fares vary depending on the time of day. However, it shouldn't cost more than SEK 300 (EUR 33,40) to travel 10 km.

Public Transportation

Storstockholms *Lokaltrafik* runs the comprehensive and generally efficient transport network throughout Stockholm county, including all metro trains, commuter trains and buses. City centre buses run along fixed routes. The SL-Center is located in the basement of the Central Station. The staff can provide free timetables and also sell city and county transport maps, SL Tourist Passes and the general Stockholm Card. SL booths can be found at all metro stations, but services are usually basis.

Bank and ATM

Banks usually open at 9:30 and close at 15:00, weekdays only, but on Thursday some branches stay open until 18:00. With an ATM card from your home bank, Swedish ATMs will allow access to cash in your account. "Bankomat" ATMs and the ForeningsSparbanken "Automat" ATMs, found adjacent to many banks and around busy public places such as shopping centres, accept Visa, MasterCard, Plus and Cirrus format bank cards, and Electron and Maestro debit cards.

Climate

Despite its northerly location, Stockholm has relatively mild summer weather compared to other locations at similar latitude, or even further south. In June the average temperatures range from about 16 to 20°C during the day.

Currency

The currency is the Swedish Krona.

Exchange rate of EUR 1,00 ⇄ SEK 8,73 as per July 2011

Electricity

Electricity supply in Sweden is AC 220 Volts, 50 Hertz. Sockets meet European regulations and use the round pin system.

Time Zone

The time zone in Sweden is Greenwich Mean Time (GMT) +1 hour in winter and +2 hours in summer.

Supporting Programme – Tours

During CINP 2012, the officially appointed local partner Risbecker International will offer various guided tours in and around Stockholm for participants and their accompanying persons. Please note that all tours will start and end at the congress venue Stockholmsmässan.



Stockholm Highlights

Sunday, 3 June 2012, 14.00 – 17.00 h
 Monday, 4 June 2012, 14.00 – 17.00 h
 Tuesday, 5 June 2012, 09.30 – 12.30 h

A tour featuring all of Stockholm's noteworthy sights!

This tour is a must for anyone who has never been to Stockholm before. We begin with *Stadshuset* (City Hall). Here the Nobel Prize festivities take place every year. After having seen the City Hall we will continue and visit *Gamla Stan* (the Old Town) with its narrow cobbled streets and gabled medieval buildings. Here we will see *Storkyrkan* (the Great Church), *Stortorget* (The Main Square) and *Kungliga Slottet* (The Royal Palace). From here we travel to *Södermalm* (the Southern Island) to savor the view (bring your camera!) from *Fjällgatan* (The Mountain Street). From here we will see the major part of the central city and the port of Stockholm.

This superb view of Stockholm will make it easy to understand why this city is frequently referred to as "the City that floats on water". From here the coach will travel to the royal island of Djurgården, passing along the famous boulevard called *Strandvägen*. We will enjoy a brief tour of this historical island before it is time to travel back to our starting point.

Cost: 360 SEK (approx. 38 EUR*) per person

For registered accompanying persons the Stockholm Highlights Tour on Sunday or Monday is complimentary and necessary to reserve prior to the congress. Please use the enclosed registration form to book this tour.



Royal Stockholm

Rub shoulders with Swedish nobility
 Monday, 4 June 2012, 09:30 – 12:30 h

What better way to explore Stockholm than to follow in the footsteps of nobility? On this excursion, we will explore all things Royal starting with the Knight's Isle. This small islet is home to the majestic Royal burial church called Knight's Church. This building forms a major part of the Stockholm skyline. From here it's onto the Old Town, passing the House of Nobility and on to see the Royal Palace of Stockholm and the Great church – the venue for the recent Royal wedding between Princess Victoria & Daniel Westling. In the Old Town, we will hear about Stockholm's most famous historical event, The Stockholm Bloodbath. We will also hear the story of King Gustav III's assassination during a masquerade ball at his own opera house. From here it's on to the Royal island of Djurgården. This island is an oasis in the heart of city. Loved by all Stockholmer's, thousands flock here each week to seek a little private space, take a romantic walk or just enjoy the beautiful scenery and wildlife. It is not uncommon to see wild deer roaming the island.

Cost: 360 SEK (approx. 38 EUR*) per person

Booking Conditions

- Prior to the 28th CINP World Congress booking is only available online via the official CINP congress website.
- Full payment in advance is required.
- All tours will be conducted in the English language.
- Exceptional circumstances beyond the control of Risbecker International may incur prices to be subject to change.
- All prices include the current VAT tax rate.
- Confirmations will be sent out upon receipt of full payment.

- Cancellation of tours are to be made in writing to Risbecker International.
- All tours are based on a minimum of 25 participants for half day tours on page 34; 15 participants for full day tours on page 35. Tours will be cancelled if the minimum number is not reached. Full refunds will be available for tours which do not take place.
- Tours cancelled after 22 May, 2012 cannot be refunded. No refund will be possible for included services not taken. Lost or unused tickets cannot be refunded.

Supporting Programme – Tours



Mariefred & Gripsholm Castle

Tuesday, 5 June 2012, 09:30 – 15:30 h

We depart Stockholm by private deluxe coach and embark on a pleasant drive through the Chateau County of Sörmland. On the approach to Mariefred, we see the magnificent Gripsholm Castle.

Gripsholm today is a time capsule of Swedish interior design from the 16th to the late 19th century, a unique collection of furniture and decorative arts from 400 years.

The Castle is internationally known for its outstanding collection of portraits called The Swedish National Collection. It features prominent Swedes from the days of Sweden's first king, Gustav Vasa.

After the guided tour of the Castle, we will walk over to the inn in Mariefred for lunch. After lunch, we can enjoy a chance to explore Mariefred, a delightful little town with a seaside feeling, before the coach departs for Stockholm.

Cost: SEK 1.250 SEK (approx. 130 EUR*) per person,
incl. light lunch



Drottningholm Palace –

Home to the Swedish Royal Family

Wednesday, 6 June 2012, 09:30 – 15:30 h

The Royal Island of Drottningholm is a 30 minute drive from the centre of Stockholm. On the way to Drottningholm, we pass by the beautiful villas, gardens and recreational areas of Stockholm's western suburbs. On the other side of the Nockeby Bridge the exquisite vista of Drottningholm Palace comes into view.

The history of the Palace is as fascinating as the buildings and grounds are beautiful. The first building of note at this location was built in 1581 by the King of Sweden, who finally christened the mansion Drottningholm (the Queen's island) for his wife.

The famous Swedish architect Nikodemus Tessin the Elder is responsible for the current appearance of the palace as well as most of the interior. The interiors of the Palace are just as noteworthy as the breathtaking palace grounds (or English garden as it's also known). Bronze sculptures by Adrian de Vries can be found in the palace gardens. On this excursion we will enjoy a private tour of the palace and the gardens before enjoying a traditional lunch in a local restaurant.

Cost: 1.050 SEK (approx. 110 EUR*) per person, incl. light lunch

- We accept no liability for loss, damage, delay, inconvenience, or direct or consequential loss, however caused, unless due to our employees negligence, in which case our liability is limited to a maximum of the tour cost.
- Tours will depart from Stockholmsmässan.
- Any dispute arising from the contract shall be settled in accordance with the law of Sweden.
- Tours are payable in Swedish Kroner (SEK), prices mentioned in *EUR are based on exchange rate as of July 2011:
EUR 1,00 = SEK 8,73

Organiser of Supporting Programme:

Risbecker International
PO Box 3112, SE-103 62 Stockholm, Sweden
Phone: +46 – 8 – 214707
Fax: +46 – 8 – 240380
E-Mail: cinp2012@risbecker.se

Please make your booking via the congress website:
www.cinp2012.com



STOCKHOLM, the capital of Sweden, is today an international metropolis and considered one of the most beautiful cities in Europe.

A gulf of the Baltic Sea encloses the city in the east with numerous bays and promontories as well as about 24,000 larger and smaller islands (archipelago). This area is called Skärgården.


Because 30 % of the city of Stockholm exists of water ways and another 30 % of parks and green areas, Stockholm probably has the greenest lungs of all European capitals, making maritime life an important aspect of the city.

Since the 13th century the Swedish capital has developed from a fishing village on the island Stadsholmen to a far spread metropolis. Built on 14 islands, Stockholm owns one of Europe's largest and best-preserved medieval city centres. In particular the original Old Town (Gamla Stan) with its historical streets and centuries old buildings, bars, hotels, restaurants and shops is perceived as one of Stockholm's highlights.

The streets still follow the medieval layout which are ideal for leisurely walks. Several of the city's major sights are here too – the Royal Palace with the Crown Jewel Exhibition, the Royal Armoury and the Tre Kronor Museum, the Cathedral from the mid-13th century and the House of Nobility.

The royal palace was established between 1690 and 1750 and belongs to the most remarkable baroque buildings of Scandinavia. It stands on the foundation of castle Tre Kronor (three crowns) which was built in the middle of the 13th century and destroyed in 1697 in a fire. With 608 rooms the royal palace is the biggest inhabited palace from a head of a state (King Carl XVI Gustav) worldwide.

The City Hall of Stockholm is a living symbol of the city, a building buzzing with activities in addition to the annual Nobel Banquet. This architecturally renowned edifice is the venue for important political debate, a busy workplace, a magnificent banqueting hall and one of Sweden's best known tourist attractions. Its 106 metre high tower also makes it a distinctive landmark in the capital.



Photographs © Stockholm Visitors Board



Max Hamilton Memorial Prize

THE INTERNATIONAL COLLEGE OF NEUROPSYCHOPHARMACOLOGY

Max Hamilton, M.D., F.R.C.P., F.R.C.Psych., D.P.M. (1912-1988) is best known for his assessment of depressive illness through psychometrics. The Hamilton Rating Scale for Depression is widely used throughout the world, and his 1960 paper on the problem of measuring the severity of depression is probably the most cited medical publication in the second half of the twentieth century. The recipient of the 2012 award will be chosen by an international scientific jury by March 2012. This prize consists of a monetary award and an engraved plaque, to be presented at the 28th CINP Congress in Stockholm, Sweden.

Previous Max Hamilton Awardees

2010: Jean-Martin Beaulieu, Université Laval, Canada	2006: Alexander Neumeister, Yale University School of Medicine, USA
2008: George Papakostas, Harvard Medical School, USA	2004: Sarah H. Lisanby, New York State Psychiatric Institute at Columbia University, USA.
	2002: Dan Stein, MRC Research Unit, South Africa.

Guidelines:

- ◆ The Max Hamilton Memorial Prize is given to a young scientist in recognition of an outstanding contribution to psychopharmacology.
- ◆ Nominations can be made by any individual; nominees need not be members of the CINP, but must be less than 41 years of age on 31st December 2012.
- ◆ The contributions may be in clinical evaluation or services, in pre-clinical or clinical research, or any combination of these.
- ◆ The contributions may be empirical advances or a theoretical construct, based on a single discovery or a cumulative body of work.
- ◆ The Awardee must commit to attendance at the 2012 Congress for at least three full days.

To submit a nomination, the following application materials must be submitted by email or hard copy in English, by the 5th January 2012 deadline:

- 1) This completed form.
- 2) No more than 500 words summarizing the basis for nomination.
- 3) An up-to-date curriculum vitae including a list of publications.

Full name of nominee: _____

Present position: _____

Address: _____

Tel: _____ Fax: _____

E-mail: _____ Date of birth: _____

Year and location of terminal degree: _____

I hereby confirm that my application is complete and that I subscribe to all regulations governing the Max Hamilton Memorial prize. If you are submitting your application by email please complete this form and send to us by fax or post.

Current date: _____ Nominee's Signature: _____

Please return completed applications to:

Shigeto Yamawaki, Chairman Fellowship Awards Committee
 Max Hamilton Memorial Prize
 CINP Central Office
 Glenfinnan Suite, Braeview House, 9/11 Braeview Place
 East Kilbride, Glasgow, G74 3XH
 Scotland, UK
 Tel: + 44 (0) 1355 244930
 Fax: + 44 (0) 1355 249959
 Email: cinp@northernnetworking.co.uk

This application will be copied for submission or to distribute to others.



CINP Pioneers in Psychopharmacology Award

THE INTERNATIONAL COLLEGE OF NEUROPSYCHOPHARMACOLOGY

The Award is given at each Congress to three individuals to honour those who have made major contributions to the field as it has developed. The contributions may be in research, clinical, or administrative areas but must be internationally recognised as significant to the growth of the field. Pioneer Awardees receive round trip economy air travel and accommodation at the 28th Congress in Stockholm, Sweden, an engraved plaque, paid registration fees and appropriate recognition at the meeting.

Previous Pioneers

2010: Per Bech, (Denmark), Salomon Langer, (Israel) and Teruo Okuma, (Japan)

2008: Jean-Pierre Changeux, (France), Samuel Gershon, (USA) and Hannah Steinberg, (UK)

2006: Leonard Cook, (USA), Fridolin Sulser, (USA), Merton Sandler, (UK)

2004: Hanns Hippus (Germany), Alfred Pletscher (Switzerland) and Herman M. van Praag (The Netherlands)

2002: Frank Ayd, Jr. (USA), Arvid Carlsson (Sweden) and Jonathan Cole (USA)

The Executive Committee selects these individuals and is soliciting candidates from psychopharmacologists around the world. Send a letter by any mode to the President, Hans-Jürgen Möller., c/o CINP Central Office proposing any nomination and the reasons why this person should be considered for an award, with details of their principal contributions to psychopharmacology by **5th January 2012.**

Please send your nominations to Hans-Jürgen Möller at the following address:

CINP Central Office
Pioneer Award
Glenfinnan Suite, Braeview House, 9/11 Braeview Place
East Kilbride, Glasgow, G74 3XH
Scotland, UK
Tel: + 44 (0) 1355 244930
Fax: + 44 (0) 1355 249959
Email: cinp@northernnetworking.co.uk

This application will be copied for submission or to distribute to others.



Rafaelsen Young Investigators Award

THE INTERNATIONAL COLLEGE OF NEUROPSYCHOPHARMACOLOGY

In 1986 Ole Rafaelsen and William Bunney were instrumental in establishing a CINP programme supporting the attendance of young scientists at the XVth CINP Congress in 1986. That programme was posthumously named the Rafaelsen Fellowship Award to honour Dr. Rafaelsen, who died in 1987.

The recipients of the 28th Congress Awards will be chosen by an international scientific jury by early March 2012. A number of Awardees will be selected and presented with Awards consisting of round trip economy air travel, up to four nights accommodation, a certificate, a cash stipend including an element for ground transportation and waived registration fees at the 28th CINP Congress in Stockholm, Sweden.

Guidelines:

- ◆ The Young Investigator Awards are open to individual's world-wide, independent of nationality, sex or race.
- ◆ Applications must be sponsored by a CINP member; self-nominations are accepted.
- ◆ Those nominated may be researchers or clinicians, but must have made a commitment to the field of neuropsychopharmacology.
- ◆ Individuals must have a doctorate degree, be working full-time in neuropsychopharmacology research, teaching, or clinical activities, have not reached his/her 36th birthday in the year in which the award is made (i.e., no older than 35 years of age as of 31 December 2012).
- ◆ Each Awardee must commit to present a poster at the 2012 Congress.
- ◆ The Awardee must commit to attendance at the 2012 Congress for at least three full days.

To submit a nomination, the following application materials must be submitted by email or hard copy in English, by the 5th January 2012 deadline:

- 1) The nominee's curriculum vitae including a list of publications.
- 2) A 500-word statement which summarizes the nominee's current work activity and explains the basis for the nomination, and include a statement of agreement to present a poster.
- 3) Sponsor's letter of recommendation.
- 4) This completed application form.

Full name of nominee: _____

Address: _____

Tel: _____ Fax: _____

E-mail: _____ Date of birth: _____

I hereby confirm that my application is complete and that I subscribe to all regulations governing the Rafaelsen Fellowship Award. You can submit your application by email, fax or post.

Current date: _____ Nominee's Signature: _____

Please return completed applications to:

Shigeto Yamawaki, Chairman Fellowship & Awards Committee

Rafaelsen Young Investigators Award

CINP Central Office

Glenfinnan Suite, Braeview House, 9/11 Braeview Place

East Kilbride, Glasgow, G74 3XH

Scotland, UK

Tel: + 44 (0) 1355 244930

Fax: + 44 (0) 1355 249959

Email: cinp@northernnetworking.co.uk

This application will be copied for submission or to distribute to others.



REGISTRATION FORM

Please forward the completed form to:

Please complete using block letters or typewriter

Hanser & Co GmbH
 PO Box 12 21
 22882 Barsbütel, Germany

Phone: +49-40-670 88 20
 Fax: +49-40-670 32 83
 Email: cinp2012@cpo-hanser.de

A. Personal Details

Ms Mrs Mr Dr Prof

for internal use only

378				
-----	--	--	--	--

Family name: _____ First name: _____

Institution/Department: _____

Mailing address: private address institute address

Street: _____

Postal code, City: _____ Country: _____

Phone: _____ Fax: _____

E-mail: _____

B. Accompanying Person

Ms Mrs Mr Dr Prof

for internal use only

378				
-----	--	--	--	--

Family name: _____ First name: _____

For registered accompanying persons the Tour – Stockholm Highlights – is included.
 Please mark with a cross if you want to participate.

3 June 2012 [40] **or** 4 June 2012 [41]

C. Registration Fees

Registration and Payment received	until 31 January 2012	until 2 May 2012	after 2 May 2012	EUR
CINP Member	[20] <input type="checkbox"/> EUR 500	[21] <input type="checkbox"/> EUR 600	[22] <input type="checkbox"/> EUR 700	EUR _____
Non-Member	[23] <input type="checkbox"/> EUR 700	[24] <input type="checkbox"/> EUR 800	[25] <input type="checkbox"/> EUR 900	EUR _____
Young Scientist *	[26] <input type="checkbox"/> EUR 300	[27] <input type="checkbox"/> EUR 350	[28] <input type="checkbox"/> EUR 400	EUR _____
Delegate from Developing Country **	[29] <input type="checkbox"/> EUR 200	[30] <input type="checkbox"/> EUR 220	[31] <input type="checkbox"/> EUR 240	EUR _____
Student ***	[32] <input type="checkbox"/> EUR 110	[33] <input type="checkbox"/> EUR 130	[34] <input type="checkbox"/> EUR 150	EUR _____
Accompanying Person	[35] <input type="checkbox"/> EUR 90	[36] <input type="checkbox"/> EUR 90	[37] <input type="checkbox"/> EUR 90	EUR _____
Total				EUR _____

* Applicants must be under 35 years of age and a copy of passport or other government-issued ID must be forwarded along with the registration.
 ** A limited number of developing countries registrations are available. To be eligible, you must reside in one of the following countries, as classified by the World Bank. List see page 29.
 *** Students aged less than 35 years who are studying for a degree including first degrees, PhD or MD but who have not yet obtained their degree. They must supply a letter from their supervisor or laboratory head to support their application for this reduced fee.

D. Social Programme

Sunday, 3 June 2012

Welcome Reception

19.30 h [39]

No. of persons

_____ free of charge for registered delegates/
accompanying persons

E. Payment

Total amount to be paid:

EUR _____

I have transferred the amount (free of any bank charges) of EUR _____ on (date) _____ to your bank:

Hanser & Co GmbH w/ CINP 2012 ZB

SHS Nordbank AG, Account number: 1000 165 432, Bank code: 210 500 00

BIC: SHS NDE HH, IBAN: DE63 2105 0000 1000 1654 32

or

I use the following credit card:

Visa **American Express** **Mastercard/Eurocard**

Name as indicated on the card: _____

Street: _____

Postal code, City: _____

Country: _____

Card number: _____

Security number: _____

(See the back of your credit card)

Expiry date: _____

I will attend the 28th CINP Congress only if my abstract has been accepted. Should my abstract not be accepted the registration fee will be refunded upon my request.

I agree that my name, institution, city and country will be published in the who is who on the internet.

I herewith accept the general conditions mentioned underneath. I agree that for the purpose of congress organisation only my personal data will be registered by using electronic data processors. My name and address will be listed in the congress list of participants and provided to sponsors and exhibitors for invitation purpose.

Date

Signature

GENERAL CONDITIONS

Registration and Payment: Registration will be confirmed if payment is received by the Congress Office by 20 May 2012. Should payment be received after this date, you will receive your confirmation at the Congress Counter in Stockholm. Please bring a copy of your bank remittance with you.

Cancellations of Congress Participation: Notice of cancellation should be sent in writing only to the Congress Office CPO HANSER SERVICE. In case of cancellation until 31 January 2012 the payment will be refunded, minus a handling charge of EUR 100. No refund will be made after 31 January 2012.

Changes to the Congress Program: In the event of cancellations by speakers or other changes in the main congress program, no full or partial refund of the registration fee can be made.

Abstract Submission: The acceptance of submitted abstracts simultaneously results in binding registration of the speaker to attend the conference. The registration fee must be paid immediately after receiving the abstract acceptance. Onsite registration for presenting authors is not possible. If the author withdraws a contribution accepted by the scientific committee and published in the abstract book, registration for the conference will be maintained and there will be no refund of the registration fees.

Force Majeure: For reasons beyond its control (such as war, strikes, lockouts, riots or any such civil disturbances, any acts of God, including but not limited to earthquakes, floods, droughts, hurricanes and volcanic eruption and any other cause of circumstance of whatsoever nature beyond its control that have an impact on the arrangements, timetables or planning of CINP congress and its corresponding activities in Stockholm, CINP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

Liability: CPO HANSER SERVICE is liable in keeping with diligence required of a prudent businessman, according to the laws of the Federal Republic of Germany. Regardless of course in law the liability of CPO HANSER SERVICE shall be limited to damages which are caused with aforethought or by gross negligence. However, this shall not affect the liability of the Congress organizer and of the persons or organizations responsible for providing means of transport or other services. The participants take part in all excursions at their own risk. Verbal agreement can only be considered as binding when confirmed by CPO HANSER SERVICE in writing.

Place of Performance, Venue of Jurisdiction: Stockholm shall be the exclusive place of performance and Hamburg venue of jurisdiction for all parties. The laws of the Federal Republic of Germany shall apply.

Congress and Exhibition Office

CPO HANSER SERVICE

Hamburg Office

Hanser & Co GmbH

Zum Ehrenhain 34

22885 Barsbüttel

Germany

Phone: +49-40-670 88 20

Fax: +49-40-670 32 83

Email: cinp2012@cpo-hanser.de

www.cinp2012.com // www.cinp.org